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1 CANCERRISKAMONGTHERELATIVESOF PROBANDS
WITH PANCREATIC DUCTAL ADENOCARCINOMA
Del Chiaro M1, Presciuttini S4, Bertacca L1, Zerbi A2, Longoni BM1,
Giovannetti A1, Cipollini G1, Caligo MA1, Boggi U1, Bevilacqua G1,
Casari G3, Civitelli V, Falconi M, Pederzoli P, Di Carlo V, Cavallini
G, Mosca F, (1) Regional Referral Center for Pancreatic Diseases,
University of Pisa, Italy; (2) Surgery, San Raffaele Hospital, Milan,
Italy; (3) Human Genetics, San Raffaele Hospital, Milan, Italy;
(4) Center of Statistical Genetics, Pisa, Italy
INTRODUCTION AND AIM: Adenocarcinoma of the pancreas is
a leading cause of cancer-related death (about 7500 deaths/year in
Italy). It is estimated that 3–5% of all pancreatic cancer cases are
caused by germline mutations in known predisposing genes, though
some families may carry genes unrelated to any identified syndrome.
In 2002, the Associazione Italiana Studio Pancreas (AISP) launched
a collaborative study to investigate these issues in Italy. PATIENTS
AND METHODS: 1) To determine cancer risks, both of pancreas
and of other sites, for the relatives of the probands with pancreatic
adenocarcinoma; 2) to collect a large number of consecutive pedi-
grees for studies of segregation and linkage analysis. Family history of
cancer and blood samples are collected from all incident cases with
pancreatic ductal adenocarcinoma. Pedigrees are recorded in a
centralized database. Selected samples are forwarded to genetic labs
for DNA analysis. RESULTS: Three collaborating centers provided
351 pedigrees ascertained consecutively, including 3685 informative
relatives. Pancreatic cancer among first-degree relatives was reported
in 25 families (7.1%), 3 including two affected relatives; this corre-
sponded to 2.8-fold risk increase compared to the general population
at age 65 and to 3.0-fold increase at age 475 years. Adding the
second-degree relatives to the analysis, 33 families (9.4%) reported
positive family history (1.8-fold risk increase at both ages 65 and475
years). Familial aggregation of cancers at any site was highly signifi-
cant; gastrointestinal and uterine cancers were present in large
excess. CONCLUSION: The present study provides the founda-
tions for investigating the genetic susceptibility to pancreatic cancer
in Italy.
2 LONG-TERM SURVIVAL AFTER PANCREATIC CANCER
RESECTION: A EUROPEAN HISTOLOGICAL EVALUATION
Wirtz M, Rockefeller University New York, New York, USA
INTRODUCTION AND AIM: The vast majority of patients
diagnosed with ductal adenocarcinoma of the pancreas (PDAC) die
within 1 year after diagnosis. Only a few patients survive more than 5
years after surgery. The current European study re-evaluates the
histology of patients surviving 45 years as well as in a matched
control group of patients surviving only 3–12 months after surgery.
The aim was to find histological differences between long- and short-
term survivors. PATIENTS AND METHODS: The entire records
of the nationwide Finnish and Danish cancer registers and the local
cancer registers of the University Hospital of Bern, Switzerland, were
screened for the diagnosis pancreatic cancer (ICD:C25) for the years
1990–1996. A matched group of patients with a survival between 3
and 12 months served as control. The original histological slides were
primarily re-evaluated by the local pathologist, thereafter by two
reference pathologists in a blinded manner. RESULTS: A total of 38
long-term survivors were histologically re-evaluated. In 24 cases the
primary diagnosis of a DAC could be confirmed. 37% of the 5-year
survivors were suffering from pancreatic lesions/tumors different
from PDAC. Papillary carcinoma and IPMT were the most common
differential diagnosis in this group followed by endocrine
tumors, chronic pancreatitis and bile duct carcinoma. Surprisingly,
the short-term survival group showed the same range of mis-
classification (36%). Surprisingly, the short-term survival group
showed the same range of misclassification in the first place.
CONCLUSION: The histological classification of ductal pan-
creatic adenocarcinoma remains difficult especially due to newly
described tumor entities like IPMTs. There is no obvious histological
difference between long- and short-term survivors in pancreatic
cancer.
3 NON-RADICAL PANCREATIC CANCER RESECTIONS
Balzano G1, Zerbi A1, Reni M2, Rocchetti S1, Leone BE3,
Vanessa C1, Di Carlo V1, (1) Surgery, S. Raffaele Hospital,
Radiochemotherapy; (2) S. Raffaele Hospital, Surgery; (3)
S. Raffaele Hospital, Pathology, Milan, Italy
INTRODUCTION AND AIM: To assess: 1. the incidence of
margins involvement; 2. the pattern of failure after non-radical
resection; 3. the value of intraoperative radiotherapy (IORT) in this
setting; 4. the effect of margins invasion on survival. PATIENTS
AND METHODS: Retrospective evaluation of prospectively
collected data. Study group: 296 patients undergoing resection for
pancreatic cancer (1990–2002). R1 status was defined histologically,
R2 status intraoperatively. Data were analysed by the x2, log-rank
and Cox analysis (covariates: radicality, diameter, stage, grading,
nodal status, adjuvant therapies). RESULTS: 175 patients (59%)
were classified as R0, 68 patients (23%) as R1 and 53 patients (18%)
as R2. The posterior margin was the most frequently involved
(69.4%). Local relapse (LR) was detected in 40% of cases after R0
resection, 39% after R1 and 55% after R2 (p=0.4). IORT was
applied in 127 patients: it has no effect to reduce local relapse in
either R0 patients (p=0.9), or R1 (p=0.3), or R2 (p=1). The
survival of R2 patients was worse than R0 patients (p50.001),
but the prognosis of R1 and R0 patients was similar (p=0.2). 2-
and 5-year survival rates were 38.6% and 14.8% in R0 patients,
32.7% and 8.6%, in R1 patients; 13.9% and 6.9% in R2
patients. The multivariate analysis confirmed that R2 status is an
independent prognostic factor (p=0.02), whereas R1 was not
(p=0.4). CONCLUSION: It is important to differentiate R1 and
R2 resections because R1 does not significantly influence LR or
survival, whereas. R2 have a worse prognosis. IORT had no effect to
reduce LR.
4 DETECTION OF TUMOR CELL DISSEMINATION IN
PANCREATIC DUCTAL ADENOCARCINOMA PATIENTS BY
CK 20 RT-PCR PREDICTS SURVIVAL
Vogel I2, Soeth E1, Ro¨der C1, Kremer B1, Kalthoff H1, Sektion
Molekulare Onkologie, UKS-H, Klinik f. Allgemeine Chirurgie u.
Thoraxchirurgie, Kiel, Germany; (2) Sta¨dtisches Krankenhaus Kiel,
Chirurgische Klinik, Kiel, Germany
INTRODUCTION AND AIM: This prospective study evaluates
the diagnostic potential of cytokeratin 20 (CK 20) RT-PCR for the
detection of disseminated tumor cells in bone marrow and blood
of patients with ductal adenocarcinoma of the pancreas and investi-
gates the prognostic value with respect to overall survival.
PATIENTS AND METHODS: Between 1994 and 2003, 172
patients with pancreatic ductal adenocarcinoma underwent surgery.
Bone marrow samples and venous blood were taken preoperatively
and analyzed for disseminated tumor cells by nested CK 20
RT-PCR. RESULTS: Disseminated tumor cells were detected in 81
(47.1%) of the 172 patients in the bone marrow and/or the venous
blood. Detection rates increased with the UICC tumor stage.
Univariate survival analysis of all 172 resected patients according to
Kaplan-Meier was statistically significant for radicality of the
operation (p50.0000), the UICC stage of the tumors (p=0.0011)
and the detection of disseminated tumor cells in bone marrow and/or
venous blood (p=0.05). Patients with well and moderately differ-
entiated tumors (G1 and G2) had a significantly longer survival
(p=0.045) than patients suffering from poorly differentiated
tumors (G3). A positive CK 20 status in the bone marrow and/or
blood of patients with G1 and G2 tumors exhibited a significant
negative prognostic impact on their survival (p=0.046).
CONCLUSION: Disseminated tumor cells can be detected in
patients with pancreatic ductal adenocarcinoma by CK 20 RT-
PCR. Detection rates are stage-dependent, and survival analysis
demonstrated statistically significant data, especially in the group of
well and moderately differentiated tumors showing a better overall
prognosis.
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5 PARTIAL RESECTION OF THE PORTAL VEIN IN
PANCREATICODUODENECTOMY IS NOT ASSOCIATED
WITH INCREASED MORBIDITY AND MORTALITY
Aselmann H, Winkler M, Oeser M, Neipp M, Mordukhovych J,
Klempnauer J, Viszeral- und Transplantationschirurgie,
Medizinische Hochschule Hannover, Hannover, Germany
INTRODUCTION AND AIM: Pancreaticoduodenectomy (Whip-
ple’s operation) is the treatment of choice for malignancies of the
head of the pancreas and the juxtapapillary region of the duodenum
and is an option in chronic pancreatitis. Especially in malignant
diseases, tumor invasion or adherence of the portal vein is a common
occurrence. Therefore, vascular resection is necessary to achieve
R0 situation. The clinical value of this procedure, however, is still
discussed controversely. PATIENTS AND METHODS: Retro-
spective analysis of the treatment results of 189 patients undergoing
Whipple’s operation from January 2000 until April 2004.
RESULTS: The two groups (with/without vascular resection) did
not differ significantly in age, gender or underlying disease. Resection
of the portal vein was performed in 31 (18%) patients, 158 (62%)
underwent surgery without vascular resection. Overall hospital
mortality in patients with and without portal vein resection (1/31,
3.2% vs 7/158, 4.4%), overall morbidity (38% vs 45%, p40.1) and
median hospital stay (25 vs 29 days, p40.1) did not differ signifi-
cantly. Postoperative hemorrhage occurred in 11% with and 15%
without portal vein resection. Reconstruction of the portal vein was
performed as end-to-end anastomosis in 22 cases (71%); in 9 patients
(29%) implantation of an alloplastic prosthesis was required,
mortality in these two groups was comparable. CONCLUSION:
Pancreaticoduodenectomy combined with partial resection of the
portal vein is not associated with increased morbidity and mortality.
Performed by an experienced surgeon, portal venous resection can
expand the resection rate without significantly endangering the
patient. Therefore this treatment option should be considered in
these otherwise irresectable patients.
6 REG IV, A HITHERTO UNDESCRIBED PRODUCT OF
THE REG GENE FAMILY, IS SPECIFICALLY EXPRESSED IN
PANCREATIC PP CELLS
Yalniz M1, Pour PM1, Lesuffleur T2, Moniaux N2, Aubert JP2,
(1) UNMC/Eppley Cancer Center 6805, University of Nebraska
Medical Center; (2) Place de Verdun, Unite 560 INSERM, Omaha,
NE, USA
INTRODUCTION AND AIM: The Reg gene family has been
implicated in a variety of functions including regeneration, prolif-
eration and malignancy. Their physiological function, however, is not
well understood. Recently, a novel member of the Reg gene family,
Reg IV, has been identified and its expression in normal and diseased
gastrointestinal mucosa including dysplasia and cancer has been
reported. Its expression in pancreatic tissue, however, has not yet
been investigated. We report, for the first time, the expression of Reg
IV in the normal and diseased pancreas. PATIENTS AND
METHODS: The expression of Reg IV was examined by a poly-
clonal antibody in five normal pancreases from organ donors, four
chronic pancreatitis, 13 pancreatic cancer specimens, and in cultured
human islet cells by multi-labeling immunohistochemistry.
RESULTS: The expression of Reg IV was limited to pancreatic
polypeptide (PP) cells. Multi-labeling technique indicated that
there were a few PP cells that did not express Reg IV. In cancer tissue,
the number of PP cells, and with that of Reg IV expression, was
significantly increased. Cultured human islet and ductal cells
immunoreacted with anti-Reg IV but not with anti-PP antibody,
indicating that pancreatic polypeptide is not the target of the Reg IV
antibody. No staining of pancreatic exocrine cells or endocrine
cells other than PP cells were observed and no cancer cells
were immunoreactive with the antibody. CONCLUSION: In the
pancreas, Reg IV is a marker for PP cells. Its upregulation seems to be
associated with hyperplasia and malignancy.
7 EARLY AND ENDURING FUNCTIONAL AND
NUTRITIONAL RESULTS OF PYLORUS PRESERVATION VS
CLASSIC WHIPPLE PROCEDURE FOR PANCREATIC
CANCER
Niedergethmann M, Shang E, Saar J, Farag-Soliman M, Willeke F,
Post S, Department of Surgery, University-Hospital Mannheim,
Mannheim, Germany
INTRODUCTION AND AIM: There have been many supportive
data that the pylorus-perserving pancreatoduodenectomy (PPPD)
might be equal to the classic Whipple pancreatoduodenectomy (PD)
in terms of oncological radicality. However, few reports are available
on the early postoperative and enduring functional changes, the
nutritional status, body composition, and the quality of life years
after surgery. The aim of this study was to compare these changes
in a retrospective and prospective setting. PATIENTS AND
METHODS: In May 1998 the standard surgical approach in the
Department of Surgery, University-Hospital Mannheim changed
from PD to PPPD. Early postoperative and enduring functional
changes, quality of life, oncological radicality, and long-term
nutritional status were compared in a group of 111 patients after
PD (1996–1998) and 128 patients after PPPD (1998–2002). In
a retrospective manner the intra- and postoperative course was
evaluated. Prospectively, we analyzed functional, nutritional, and
oncological outcome after 5 years in PD, and after 2 years in
PPPD patients. RESULTS: The PPPD group was significantly
favourable for: operating time (PPPD: 341+/774 vs PD: 386+/
789 min), blood loss (793+/7565 vs 1000+/7590 ml), blood
transfusions (416+/7691 vs 653+/7776 ml), delayed gastric
emptying (6 vs 13%), and hospital stay (20 vs 24 days). However,
more T4 stages were diagnosed in the PD group (PPPD 3% vs PD
11%), and more extended (venous) resections were performed in
the PD group (PPPD 7% vs PD 24%). Morbidity (32% vs 30%)
and mortality (5% vs 3%) did not differ between the two groups.
After at least 2 (PPPD, n=22) and 5 (PD, n=16) years, there was
no difference in global quality of life in recurrence-free patients.
While the preoperative body weight was reached after 4 months
(median) in the PPPD group, it was reached after 6 months
(p50.05) in the PD group. Bioelectrical impedance analysis revealed
a significantly lower total body water (55% vs 60%) and signifi-
cantly higher total body fat (26% vs 18%) in PPPD than in PD
patients. Long-term follow-up showed no significant differences in
survival between both groups. CONCLUSION: Beside favourable
postoperative outcome in specific aspects and equal oncological
outcome, pylorus preservation seems to have advantages in enduring
functional and nutritional status years after surgery for pancreatic
cancer.
8 SURGICAL TREATMENT OF SECONDARY TUMOURS
TO THE PANCREAS
Caprotti R2, Crippa S2, Bovo G1, Mussi C2, Bonardi C3, Sartori P2,
Angelini C2, Uggeri F2, (1) Department of Pathology, University
of Milan-Bicocca; (2) Department of Surgery, University of
Milan-Bicocca; (3) Department of Gynaecology, University of
Milan-Bicocca, Vimercate, Italy
INTRODUCTION AND AIM: Unlike primary pancreatic carci-
noma, metastases to the pancreas are rare and their resection may be
performed as palliative treatment. The aim of this study was to review
our experience with the operative management of pancreatic
metastases. PATIENTS AND METHODS: Between January 1994
and December 2003, 13 patients (9 female and 4 male, median age
58.8 years, range 36–79) were admitted to our institution for meta-
static lesion to the pancreas. The clinical features, treatment and
results were examined. RESULTS: Primary tumours were renal cell
carcinoma (n=5), lobular carcinoma of the breast (n=3), endome-
trioid carcinoma of the ovary (n=1), colonic adenocarcinoma
(n=1), jejunal leiomyosarcoma (n=1), melanoma (n=1) and non-
small cell lung cancer (n=1). The median interval between primary
tumor and pancreatic metastases was 55.9 months. 6 patients (46%)
were asymptomatic. The other 7 patients presented with jaundice,
pain, duodenal obstruction. Two patients with extrapancreatic
disease underwent palliative surgery. In the remaining patients
operative procedures performed included seven pancreaticoduo-
denectomy and four distal pancreatectomy with splenectomy.
Postoperative mortality was nil, morbidity rate was 30%. Two
patients who underwent palliative surgery died after 7 and 9 months.
Median survival of the resected patients was 26 months (range 13–
95). 5 patients died of disease, 8 are alive, 3 with disease. A trend
toward improved survival, even if not statistically significant, was
observed in renal carcinoma patients. CONCLUSION: Surgical
resection can be performed safely in patients with isolated metastases
to the pancreas. Long-term survival and good palliation may be
achieved.
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9 PANCREATIC METASTASES FROM NON-RENAL CELL
CARCINOMA
Crippa S, Salvia R, Bassi C, Falconi M, Butturini G, Molinari E,
Cavallini A, Pederzoli P, General Surgery, University of Verona,
Verona, Italy
INTRODUCTION AND AIM: Isolated pancreatic metastases are
uncommon and the value of their management is poorly defined. We
review our experience with pancreatic metastases different from renal
cell carcinoma, better defined in literature. PATIENTS AND
METHODS: We analysed histology, management and long-term
results of 12 (7 female, 5 male, mean age 62 years, range 35–80)
patients with a diagnosis of pancreatic metastasis different from renal
cell carcinoma observed in our department from 1994 to June 2004.
RESULTS: Over 2601 patients discharged with a diagnosis of
pancreatic neoplasm were found: 41 (1.6%) with pancreatic meta-
stasis, 29 (70.7%) were from renal cell carcinoma, 12 (29.3%) from:
breast (n=3), colonic carcinoma (n=2) and one patient respectively
from bladder, endometrium, adrenal gland and prostate carcinomas,
melanoma, parametrium leiomyosarcoma and chronic lymphocytic
leukaemia. In two cases metastases were synchronous (adrenal
gland cancer and LLC), in the others the median disease-free interval
was 77 months. Two patients had multiple metastases while in the
others the metastases were located in the head (n=6), body-tail
(n=4). Two patients did not receive any surgical treatment
(LLC and prostatic cancer) and underwent chemotherapy. Three
patients underwent surgical palliation. The remaining patients
underwent atypical resection (n=2), distal pancreatectomy (n=1)
and pancreaticoduodenectomy (n=4). Overall mean survival is 21.6
months (range 3–72); the resected patients had a mean survival of
28.6 (12–72) and the unresected patients of 12 months (3–42).
CONCLUSION: Pancreas rarely can be the site of metastatic
diseases, typically many years after primary tumor treatment.
Surgery, combined with medical therapy, may improve survival.
10 ASSESSMENT OF POTENTIALLY RESECTABLE
PANCREATIC MALIGNANCY WITH LAPAROSCOPY AND
INTRAOPERATIVE ULTRASOUND
Doucas H, Sutton C, Zimmermann A, Dennison A, Berry D,
Department of Hepatobiliary and Pancreatic Surgery, Leicester
General Hospital, Leicester, UK
INTRODUCTION AND AIM: Staging laparoscopy for pancreatic
malignancy is controversial. Our aim was to assess the efficacy of
laparoscopy with intraoperative ultrasound (IOUS) in the manage-
ment of patients with potentially resectable pancreatic carcinoma.
PATIENTS AND METHODS: The study involved patients
undergoing laparoscopy and IOUS over a period of 32 months. Entry
criteria were radiological (CT or ultrasound) diagnosis of potentially
resectable pancreatic carcinoma, and no evidence of metastases.
Possible resectability was defined as up to a 5-cm pancreatic head
mass, or a body or tail mass of any size. RESULTS: 91 patients were
included, 48 men and 43 women, aged 21–83 (mean 63). 25 (27.5%)
patients were found to have undetected peritoneal or liver disease.
Seven (7.7%) patients had been misdiagnosed: lymphoma (n=1),
sarcoma (n=2), ampullary tumour (n=1), chronic pancreatitis
(n=3). 36 (39.6%) patients were suitable for curative resection. One
of these was deemed unfit following response to anaesthetic at
laparoscopy. Of the remainder, 16 (45.7%) underwent potentially
curative resection. Reasons for irresectability were lymph node
metastases (n=9), mass too large or involving vessels (n=8), unde-
tected liver metastases (n=2). A further group of 14 patients
underwent bypass surgery for gastric outlet obstruction.
CONCLUSION: Laparoscopy and IOUS avoided open surgery in
42 (46%) of the patients studied. It should therefore be utilised in the
preoperative staging of pancreatic tumours.
11 ALCOHOL: A RISK FACTOR FOR PANCREATIC
CANCER EVEN WITHOUT INDUCTION OF CLINICALLY
APPARENT CHRONIC PANCREATITIS?
Leder GH3, Muche R1, Stra¨ter J2, Beger HG3, Henne-Bruns D3,
Prokopczyk B4, (1) Department of Biometry, University of Ulm; (2)
Department of Pathology, University of Ulm; (3) Department of
Surgery I, University of Ulm, Ulm, Germany; (4) Department of
Pharmacology, College of Medicine, Pennsylvania State University,
Hershey, USA
INTRODUCTION AND AIM: The role of alcohol in the etiology
of pancreatic cancer remains controversial. Furthermore some
epidemiological studies may have been confounded by tobacco smok-
ing. The more generally accepted link between alcohol consumption
and pancreatic cancer is through pancreatitis, particularly chronic
pancreatitis. Clinically apparent pancreatitis, however, is estimated
to explain only 0.1–5% of pancreatic cancer cases. PATIENTS AND
METHODS: We tested the hypothesis that if alcohol were a risk
factor itwouldaccelerate thedevelopmentofpancreaticcancer.Ageat
diagnosis of histologically or cytologically confirmed adenocarcinoma
of the pancreas among male smokers and nonsmokers who consumed
455 g alcohol/day (group A) was compared with those whose aver-
age daily consumption was 510 g alcohol (group B) using the Cox
proportional hazard model. The model was adjusted for smoking and
history of chronic pancreatitis. Data were collected from 1982 to
2004. RESULTS: The Cox proportional hazard model, adjusted for
patients with chronic pancreatitis, showed that nonsmoking group A
patients (n=16, mean age 57.1, SE 1.95, 1 case with chronic
pancreatitis) acquired pancreatic cancer at a younger age than group
B patients (n=68, mean age 62.6 years, SE 1.31, 2 cases with chronic
pancreatitis, p50.05). Similarly, smoking group A patients (n=58,
mean age 56.7 years, SE 1.09, 4 cases with chronic pancreatitis) were
younger than group B patients (mean age 59.6 years, SE 1.56,
p50.05, 2 cases with chronic pancreatitis). CONCLUSION:
Greater quantities of alcohol may be a risk for pancreatic cancer even
prior to induction of clinically apparent chronic pancreatitis.
12 COMPARATIVE EPIDEMIOLOGICAL-
PATHOHISTOLOGICALSTUDIESONPANCREATICCANCER
Silverman D1, Pour PM2, (1) Cancer Epidemiology, National
Cancer Institute; (2) UNMC/Eppley Cancer Center, 6805, Omaha,
NE, USA
INTRODUCTION AND AIM: Several factors have been proposed
as etiological factors of pancreatic cancer, including tobacco, diet,
environmental pollution and obesity. It is also estimated that around
4% of the disease is genetic. There is, however, no information about
a relationship between the causative factor and the histological type
of the tumors. It is presently unclear whether the same histological
and biological type of cancer develops in obese people or in persons
with familial pancreatic cancer. The prevalence of ductal type of
adenocarcinoma in more than 90% of pancreatic cancer cases casts
doubts about a relationship between the causative agents and tumor
type. The rarely occurring cancers, on the other hand, could be more
promising for the establishment of such a relationship as shown for
certain rare types of tumor. PATIENTS AND METHODS: A
prospective epidemiological study was performed in 230 cases. Of
these, the histological tumor tissue from 80 cases collected from the
local hospitals were found suitable for the study. Comparison was
made between the histological classification of tumors and available
epidemiological data. RESULTS: Morphologically, 55 of 80 classi-
fiable tumors were ductal adenocarcinomas, 9 cystadenocarcinoma,
3 anaplastic. The remaining 13 tumors were of uncommon type (5
microglandular, 4 small cell, 3 adenosquamous cell and 1 squamous
cell carcinomas). Correlation of these 13 tumors with the epide-
miological data showed a strikingly high incidence of microglandular
adenocarcinomas that occurred in four cases, all four were middle-
aged black obese women; three of these four cases had family history
of cancer and two had history of exposure to agricultural toxins.
There also seemed to be an association between adenosquamous cell
carcinoma, race, gender, obesity and exposure to toxins, similar to
the situation with the microglandular carcinoma cases. All cases with
small cell (anaplastic) carcinomas occurred in smokers and mostly in
men (3 of 4). CONCLUSION: The presented data may be the first
message that such correlative studies could be useful when done on a
broader spectrum of investigation. Multidisciplinary work employing
cohort and genetic epidemiology, bioinformatics, pathomorpholo-
gical and molecular biological information could shed more light on
this dark area of our knowledge.
13 QUALITY OF LIFE (QOL) IN PATIENTS AFTER
PANCREATICODUODENECTOMY FOR DUCTAL
ADENOCARCINOMA OF THE PANCREATIC HEAD
Schniewind B3, Bestmann B1, Vogel I2, Fa¨ndrich F3, Henne-Bruns
D4, Kremer B3, Kuechler T1, (1) Reference Center Quality of Life in
Oncology, University Hospital Kiel, Kiel, Germany; (2) Surgery,
Kiel Municipal Hospital, Kiel; (3) Clinic for General and Thoracic
Surgery, University Hospital Kiel, Kiel, Germany; (4) Clinic for
Visceral- and Transplantation Surgery, University of Ulm, Ulm,
Germany
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INTRODUCTION AND AIM: QoL was evaluated in patients who
underwent pancreaticoduodenectomy (PD) for ductal adeno-
carcinoma of the pancreatic head. Special attention was given to the
influence of extended lymphadenectomy and classic Whipple
procedure (PPD) versus pylorus-preserving pancreaticoduode-
nectomy (PPPD). PATIENTS AND METHODS: From 1993 to
03/2004 QoL was analyzed in a prospective single-center study in 91
of 169 patients, who underwent resection of the pancreatic head for
ductal adenocarcinoma. All patients received either classic PPD
(n=34) or comparable PPPD (n=57). Most patients had additional
extended lymphadenectomy (ELA; n=70), remaining patients
underwent regional lymphadenectomy (RLA; n=21). QoL was
assessed by the EORTC QLQ-C30 supplemented by a disease
specific module. Data were collected preoperatively, before
discharge, 3, 6, 12, and 24 months after surgery. The statistical w2-
test, Mann-Whitney u-test, Kaplan-Meier analysis and Cox regres-
sion. RESULTS: No significant difference was found concerning
long-term survival between the PPD and the PPPD group as well as
between the ELA and the RLA group. General QoL significantly
decreased after surgery and only slowly recovered to almost pre-
operative level within the period of 24 months. This applied for most
QoL scales. Compared to the RLA group, patients with ELA
reported clinically significantly higher levels of diarrhea, pain and
poorer global health. Compared parameters of QoL between PPD
and PPPD showed disadvantages particularly concerning pain scales
in the PPPD. However, the PPPD group included a significantly
higher proportion of ELA patients. CONCLUSION: Comparison of
surgical techniques of reconstruction did not demonstrate significant
differences in terms of general QoL, but an extension of lymphade-
nectomy seemed to impair the patients’ QoL.
14 SURGICAL TREATMENT OF PANCREATIC
METASTASES OF RENAL CELL CARCINOMA
Sotiropoulos GC, Lang H, Brokalaki E, Broelsch C, General Surgery
and Transplantation, University Hospital Essen, Essen, Germany
INTRODUCTION AND AIM: The pancreas is an unusual site for
metastases of renal cell carcinoma (RCC), sometimes occurring
many years after nephrectomy. We present herein two cases of
pancreatic metastases of renal cell carcinoma, 17 and 19 years after
the primary diagnosis. PATIENTS AND METHODS: In the first
case, metastases were encountered in the head of the pancreas, right
upper arm and right lobe of the thyroid gland. In the second case,
tumor was found in the tail of the pancreas and remnant of the right
kidney. This was the third recurrence of the original tumor after an
initial left nephrectomy and two subsequent partial right nephrec-
tomies in the past. Treatment in the first case consisted of excision of
the tumor in the right upper arm, Whipple operation, and thyr-
oidectomy. In the second case, a distal pancreatectomy and rest right
nephrectomy were undertaken. RESULTS: Both patients recovered
from the operations without complications and remain free of
tumor in follow-up periods of 54 and 8 months, respectively.
CONCLUSION: Resection of RCC metastases involving the
pancreas provides satisfactory long-term survival, and should be
undertaken in selected cases.
15 HIGH MUC1 CONCENTRATION PREDICTS ADVERSE
OUTCOME IN PATIENTS WITH PANCREATIC CANCER
Piemonti L1, Balzano G2, Zerbi A2, Scaltrini F2, Pontillo M1, Sordi
V1, Mercalli A1, Di Carlo V2, (1) Experimental Surgery; (2) Surgery,
S. Raffaele Hospital, Milan, Italy
INTRODUCTION AND AIM: MUC1 is a polymorphic, highly
glycosylated, type I transmembrane protein expressed by ductal
epithelial cells of many organs including pancreas. MUC1 is over-
expressed and differentially glycosylated by pancreatic ductal
adenocarcinomas and there is evidence in vitro that it could contri-
bute to invasive and metastatic potential by cell surface adhesion
properties modification and by dendritic cell function modulation.
The aim of this study was to investigate the prognostic impact in vivo
of MUC1 in patients with pancreatic cancer. PATIENTS AND
METHODS: MUC1 concentrations were measured prospectively in
155 patients with histologically confirmed pancreatic cancer at the
diagnosis. MUC1 concentrations were related to patient outcome by
both univariate and multivariate analysis. RESULTS: Patients with
high concentrations of MUC1 (H-MUC1: 425 units/L; 31.6% of
patients) had a significantly shorter overall survival pattern than those
with low concentrations (L-MUC1) (median survival: 175+32 vs
350+44; p=0.0017). As a prognostic factor, MUC1 was indepen-
dent of tumor size, presence of metastasis, surgery treatment, and
patient age. MUC1 was also predictive of outcome irrespective of the
type of therapy administered, i.e. whether chemotherapy or radio-
therapy was administered. As well as being prognostic in the total
population of patients, MUC1 also predicted outcome in different
subgroups of patients, including those submitted to resective surgery
node-negative and node-positive disease, high and low grading.
CONCLUSION: Assay of MUC1 is a relatively inexpensive,
convenient, and noninvasive method for evaluating prognosis in
newly diagnosed pancreatic cancer patients.
16 RE-RESECTIONS FOR TUMOROUS PANCREATIC
LESIONS – A WORTHWHILE RISK IN SELECTED PATIENTS
Leder GH2, Stra¨ter J1, Beger HG2, Henne-Bruns D2, (1) Pathology;
(2) Surgery I, University of Ulm, Ulm, Germany
INTRODUCTION AND AIM: Re-resections for tumorous
pancreatic lesions are controversial due to their putative high risk and
doubtful prognosis. PATIENTS AND METHODS: Patients with
re-resections for recurrent or secondary tumor after resection for a
pancreatic neoplasm or chronic pancreatitis were selected from our
pancreatic tumor database (1992–2004). RESULTS: 14 patients (8
male, 6 female, median age 59 years) underwent re-resections. There
were 3 groups of patients: (A) 7 with malignant tumor at both
operations (5 adenocarcinoma, 1 serous cystadenocarcinoma, 1
chronic pancreatitis with ductal dysplasia but CA19-9 43500 U/ml
after first resection and recurrence within 9 months); (B) 5 with
primary benign tumorous lesions and secondary malignant tumor
(2 chronic pancreatitis, 1 mucinous cystadenoma with chronic
pancreatitis, 1 islet cell adenoma with chronic pancreatitis, 1
borderline-IPMT); and (C) 2 with benign tumors at both resections
(1 adenoma of Vater’s papilla, 1 IPMT-adenoma). Primary resec-
tions were: 5 (pp)Whipple’s, 4 duodenum-preserving pancreatic
head, 3 left, 1 corpus resection, 1 ampullectomy. Re-resections were:
4 (pp)Whipple’s, 3 subtotal head/corpus, 1 left resection, 6
pancreatectomies. Median operating time of re-resections, estimated
intraoperative blood loss, stay in the intensive care unit and post-
operative hospital stay were 350 min, 1000 ml, 6 and 18 days,
respectively. Major complications were 1 intra-abdominal bleeding
and 1 subphrenic abscess. Mortality was 0%. Median survival after
first and second resection was: (A) 31 and 19 months and (B) 91 and
20 months, respectively. CONCLUSION: Re-resections for
pancreatic tumorous lesions may be performed safely and with
considerable survival in selected patients.
17 PATTERNS OF PRIMARY FAILURE FOLLOWING
DUODENOPANCREATECTOMY FOR AMPULLARY AND
PANCREATIC HEAD ADENOCARCINOMA
Hompes R, Topal B, Abdominal Surgery, University Hospital
Gasthuisberg, Leuven, Belgium
INTRODUCTION AND AIM: Survival following duodenopan-
createctomy is determined by the primary localization of the peri-
ampullary carcinoma. The aim of the present study was to analyze the
pattern of failure and clinicopathological factors influencing the
disease-free survival after curative resection of ampullary and
pancreatic head adenocarcinoma. PATIENTS AND METHODS:
Between 1998 and 2001, 88 consecutive patients with ampullary
(n=36) and pancreatic head (n=52) adenocarcinoma underwent
duodenopancreatectomy with curative intent (R0). Multivariate
analysis was performed using Cox proportional hazard technique in
order to determine prognostic factors following surgery. RESULTS:
The estimated 5-year overall survival (OS) and disease-free survival
(DFS) rates were 31.8% and 35.4%, respectively, for all patients.
DFS was significantly better after resection of ampullary as compared
to pancreatic head carcinoma, i.e. 60.8% vs 16.4% (p=0.0001),
respectively. In patients with ampullary carcinoma, cancer recurrence
was determined by the number of lymph nodes metastases (p=
0.009) and lymph vessel invasion (p=0.025). Maximum tumour
diameter (p=0.044) was found to be the only significant variable to
predict cancer recurrence in patients with pancreatic head carci-
noma. Cancer recurrence occurred in 12/36 (33%) and 40/52 (77%)
patients after resection of ampullary and pancreatic head carcinoma,
respectively. In both groups the dominant site of first recurrence was
intra-abdominal, 100% (12/12) in patients with ampullary cancer
and 92.5% (36/40) in patients with pancreatic head adenocarcinoma.
CONCLUSION: The most common site of primary recurrence after
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curative surgery of ampullary and pancreatic head adenocarcinoma is
intra-abdominal. Therefore, the search for new and effective loco-
regional (neo-)adjuvant therapeutic modalities should further be
stimulated.
18 PANCREATICOGASTROSTOMY, MORE THAN AN
ALTERNATIVE!
Satyadas T, Groot Wassink T, Habbab Y, Berry M, Iadarola M,
Sinclair M, Rae D, Eastern Hepatobiliary and Pancreatic Unit,
Ipswich Hospital, Ipswich Suffolk, UK
INTRODUCTION AND AIM: Management of the pancreatic
stump following pancreaticoduodenectomy (PD) is still very much
debated. Traditionally, the pancreatic stump is anastomosed to the
jejunum. Recently, there has been an increased interest in pancrea-
ticogastrostomy (PG), as it is thought it may be safer. However,
pancreaticojejunostomy is still the most common method. Our aim
was to assess the safety of PG in terms of major morbidity, mortality
and relaparotomy rates. PATIENTS AND METHODS: Prospec-
tive data were collected on 48 consecutive patients who had
pancreaticogastrostomy for the pancreatic stump as part of PD from
January 2001 to April 2004 in a single institution. All PGs were made
with a 3-cm pancreatic remnant being telescoped into the gastric
lumen with stenting of the main pancreatic duct (Dunk method). We
collected data on pre-operative clinical and pathological features,
peri-operative parameters, morbidity, relaparotomy and mortality
rates. The main outcome measures were major morbidity, mortality
and relaparotomy rates. RESULTS: Of the 48 patients who had
PG, there were 2 in-hospital deaths (4.2%). One was due to
cerebrovascular accident and the other secondary to sepsis from
a pancreatic leak. There were 7 patients with major morbidity
(14.6%). Of these, 5 were anastomotic leaks, of which 4 were
pancreatic and 1 was biliary. All these patients were treated
successfully by CT-guided percutaneous drainage and antibiotics.
There were 2 cases of significant gastric stasis proved on contrast
imaging. One of 48 patients required relaparotomy (2.1%).
CONCLUSION: PG is a safe procedure with low major morbidity,
mortality and relaparotomy rates.
19 SINGLE LOOP VERSUS ISOLATED ROUX LOOP
PANCREATICOJEJUNOSTOMY FOLLOWING
PANCREATICODUODENECTOMY
Kaman L, Behera A, Singh R, Katariya RN, General Surgery,
PostGraduate Institute of Medical Education and Research,
Chandigarh, India
INTRODUCTION AND AIM: The aim of this study was to review
the experience of single loop versus isolated Roux loop pancreati-
cojejunostomy in a series of patients undergoing pancreatic head
resection. PATIENTS AND METHODS: A retrospective review
involving 111 patients who underwent pancreatic head resections
over a 13 year period (1990–2002) for malignant (n=106) and
benign (n=5) disease was performed. Reconstruction of the
pancreatic remnant was done using a single loop in 51 patients and by
an isolated Roux loop in 60 patients. All pancreatic anastomoses were
performed as a duct to mucosa anastomosis, in two layers, with
pancreatic stent and closed suction drainage. Pancreatic fistula was
defined as drainage of 450 ml of amylase-rich fluid for 47 days
postoperatively. RESULTS: The two groups were comparable as
regards their demographic profiles, preoperative laboratory values
and disease status in terms of pathology, pancreatic texture and
pancreatic duct diameters. The overall incidence of pancreatic
anastomotic leak was 10.8% (12/111) and was similar in both the
single loop (11.7%) and isolated Roux loop pancreaticojejunostomy
(9.8%). Isolated Roux loop pancreaticojejunostomy was associated
with a significant prolongation of operative time (7.25+1.14 vs
6.7+1.12 h) (p50.05) and the need for more blood transfusion
(2.25+0.84 vs 2.62+0.69 units) (p50.05). There was no significant
difference in the morbidity or mortality between the two groups. 45%
(23) of patients had complications in the single loop group and 48%
(29) of patients had complications in the isolated group. There were
4 (7.8%) deaths in the single loop group and 5 (8.3%) in the isolated
group (p40.05). CONCLUSION: There does not appear to be a
significant difference in the rates of pancreatic fistula following either
method of reconstruction. However, performance of an isolated
Roux loop pancreaticojejunostomy entails a prolongation of opera-
tive time and intraoperative requirement of blood.
20 CENTRAL PANCREATECTOMY: INDICATIONS,
TECHNIQUE, EARLY AND LATE RESULTS
Iacono C, Bortolasi L, Frisini M, Serio G, Surgery and
Gastroenterology, University of Verona, Verona, Italy
INTRODUCTION AND AIM: Central pancreatectomy (CP) is an
operation that allows resection of benign or low malignancy tumors
located in the pancreatic isthmus that are not suitable for enuclea-
tion. The main advantage of this operation compared with major
resections is that it permits sparing of normal pancreatic parenchyma.
PATIENTS AND METHODS: The operation is carried out by
exposure of pancreatic neck involved by the lesion and incision of the
peritoneum along the superior and inferior margin of the part of the
gland to be resected. Thereafter the gland is dissected from the
splenic artery and porto-mesenteric axis and divided with a 1-cm
clear margin. The cephalic stump is sutured and the distal stump is
anastomosed end-to-end or end-to-side with a Roux-en-Y jejunal
loop. We treated 20 patients with this technique. The indications for
CP were: serous cystadenoma in 7, mucinous in 3, solid cystic
papillary tumor in 1, metastasis from renal cancer in 1 and endocrine
tumor in 8 patients. RESULTS: Mortality rate was 0% and
morbidity rate was 35%; pancreatic fistula occurred in 25% of the
cases and was treated conservatively. Mean postoperative hospital
stay was 18 days. Postoperative endocrine and exocrine functional
tests were normal in all controlled patients. All the patients are alive
without clinical and imaging evidence of disease. CONCLUSION:
CP is a safe technique for benign or low malignancy tumor of the
pancreatic neck that allows cure of the tumor with evident functional
results without increasing the risk for the patient.
21 CURATIVE RESECTION FOR LEFT-SIDED
PANCREATIC MALIGNANCY
Bergenfeldt M, Burcharth F, Moesgaard F, Department of
Gastrointestinal Surgery, Copenhagen University Hospital Herlev,
Herlev, Denmark
INTRODUCTION AND AIM: Due to their late presentation,
malignancies of the pancreatic body and tail generally have a worse
prognosis than those of the head. Selection for surgery has been made
easier by improved diagnosis and staging. Consequently, reports of
long-term survival after resection of left-sided malignancy have
emerged. Here we report 8 men and 12 women (median age 63 years;
range 49–75), who were operated on because of a malignant tumour
of the pancreatic body and/or tail. PATIENTS AND METHODS:
Patient charts were analysed for all resections of a malignant tumour
of the body and tail of the pancreas from 1977 to 2003. RESULTS:
Sonography was positive in 15/17 (88%) patients and CT scanning in
9/9 (100%). Preoperative cytology was positive in 10/20. 14 patients
had distal pancreatic resection; 5 with resection of stomach, renal
capsule, portal vein (2) and renal vein. Six patients had total
pancreatectomy with three portal vein resections. Median operating
time was 360 min, median blood loss 2500 ml and median tumour
size 5 cm. Adenocarcinoma was present in 16, mucinous cystade-
nocarcinoma in 2, and endocrine cancer in 2 patients. Stage IA was
present in one case, stage IB in three, stage IIA in two, stage IIB in
seven and stage III in seven cases. R0 and R1 radicality was achieved
in 17 and 3 cases, respectively. 60% of patients had postoperative
complications such as wound infection (4/20), wound dehiscence (2/
20), abscess (2/20), postoperative jaundice (1/20), intra-abdominal
bleeding (1/20), and anastomotic bleeding (1/20). Medical compli-
cations were pneumonia (3/20), and pleural exudate (2/20). One
patient died of sepsis with multiple organ failure. Median survival of
all patients was 17 months (range 0–176; IQR 11–44). The subgroup
with ductal adenocarcinoma had a median survival of 17 months
(range 0–174; IQR 12–44), and 5-year survival was 15.6%.
CONCLUSION: (1) Selected patients can be resected for cure, but
resection of adjacent organs or vessels may be needed. (2) The
postoperative mortality was 5%, i.e. similar to Whipples operation.
(3) 60% of patients had postoperative complications. (4) Median
survival was 17 months. The subgroup with ductal adenocarcinoma
had a median survival of 17 months and 15.6% had a 5-year survival.
22 PANCREATIC CARCINOMA: EFFECTIVE DIAGNOSIS
WITH DUAL-PHASE SPIRAL CT, DSA OR ERCP ?
Thanos L1, Mylona S1, Goumas K2, Papaioannou N3, Ellinas P1,
Karaliotas K3, Batakis N1, (1) Radiology; (2) Gastrointestinal; (3)
Surgical, Red Cross Hospital; Athens, Greece
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INTRODUCTION AND AIM: To present the effectiveness,
accuracy and sensitivity of dual-phase spiral CT, DSA and ERCP, for
the preoperative staging of a pancreatic carcinoma and estimate its
resectability. PATIENTS AND METHODS: In 63 patients with
pancreatic tumor (staged resectable from the US) we proceeded with:
dual-phase spiral CT, ERCP, and DSA preoperatively. The surgery
and histopathology of the tumor established the diagnosis.
RESULTS: 51 patients (80.64%) had malignant tumor and the rest
12 (19.36%) had benign tumor. The distinction between malignant
and benign tumors was: sensitivity of CT 88% and of ERCP 81%.
The histopathological diagnosis was confirmed in 43 patients from
surgical specimens and in 17 from percutaneous core biopsy. The
accuracy of CT for the arterial infiltration was 85% and of the DSA
80%. The infiltration of veins was demonstrated with CT in 64% and
with DSA in 54% of the patients. The accuracy of DSA was 81% and
of CT 56%. The accuracy of CT for local non-resectability
(combining extrahepatic tumor invasion and vessel infiltration) was
90%. CONCLUSION: Dual-phase spiral CT is a safe, noninvasive,
and accurate technique for detecting and staging of pancreatic
carcinoma. Angiography should no longer be a routine diagnostic
procedure.
23 KAUTSCH-WHIPPLE VERSUS PYLORUS-
PRESERVING DUODENOPANCREATECTOMY IN THE
TREATMENT OF PANCREATIC HEAD CANCER – A
PROSPECTIVE CONTROLLED LONG-TERM AND
EXTENDED RANDOMIZED TRIAL
Paquet KJ, Clinic Werlich-Barie´ Bad Kissingen, Bad Kissingen,
Germany
INTRODUCTION AND AIM: The last decades’ positive results of
pancreaticoduodenectomy in the management of pancreatic and
periampullary carcinoma have supported a rebirth of the Kautsch-
Whipple procedure. By the introduction of preservation of the gastric
antrum and pylorus by Traverso the operating risk has been reduced
and the technique simplified. In many retrospective studies it could
be demonstrated that both techniques yield the same results.
However, it is still controversial, if the Traverso operation is onco-
logically equal to the Kautsch-Whipple procedure; moreover, none of
these controversial questions have been addressed in a prospective
controlled randomized trial. Thus, our group started such a trial420
years ago and was able to follow up all surviving patients over this
period. PATIENTS AND METHODS: From 121 patients referred
to the Department of Medicine and Surgery of the Heinz Kalk-
Hospital Bad Kissingen from 1 January 1984 to 1 January 1994, 40
patients were selected after having been investigated and declared as
resectable. Full written consent was obtained before the operation;
the study was carried out in accordance with the Helsinki declaration.
23 patients were randomly allocated to the Kautsch-Whipple
procedure (group I) and 17 to the Traverso operation (group II)
using the sealed-envelope method. Postoperatively all surviving
patients were followed up after 6 months and thereafter every year by
endoscopic, radiological and functional exocrine and endocrine
investigations up to 20 years. RESULTS: One patient in group I died
of pancreatic fistula during the first 30 postoperative days; the
hospital mortality in group II was nil. Long-term survival according
to Kaplan-Mayer after 10 years was 13% in group I and 20% in group
II. After 20 years the survival in group I was stable at 20%, whereas in
group I it was 6% which is a significant difference. In addtion,
digestive and exocrine functions were better restored in group II.
CONCLUSION: Thus it could be shown in the first worldwide
prospective controlled randomized trial that there is no oncologic
difference between Kautsch-Whipple and Traverso operation in the
treatment of pancreatic head cancer. Moreover the latter procedure
guarantees better nutritional and exocrine recovery and is technically
easier to perform. Last not but not least on a long-term basis this
operation makes a significantly longer survival possible.
24 PROGNOSTIC RELEVANCE OF CYTOKERATIN
20-ASSOCIATED TUMOR CELL DETECTION IN
PANCREATIC AND PERIAMPULLARY CANCER
Wolters HH1, Dieler M1, Schleicher C1, Schubert S2, Mundel T1,
Senninger N1, Colombo-Benkmann M1, (1) Department of General
Surgery, University of Munster, Munster, Germany; (2) Molecular
Biology, Laboratory of Molecular Oncology, Munich, Germany
INTRODUCTION AND AIM: The objective of the present
prospective study was to evaluate the prognostic relevance of
disseminated tumor cells detected by cytokeratin (CK) 20 RT-PCR
in bone marrow (BM) and venous blood (VB) of patients
with pancreatic and periampullary cancer. PATIENTS AND
METHODS: Oncologic pancreatic resection was performed in
patients with adenocarcinoma of the pancreas/papilla of Vater
(n=45/n=13) (male:female 35 : 23; age 39+11 [31–83] years) from
05/2000 to 10/2003. Mononuclear cells were isolated from BM and
VB samples followed by RNA extraction, RT-PCR for histonic RNA
as quality control BM samples and CK20-specific RT-PCR. Tumour
stages were defined according to UICC (2002), survival analysis was
performed according to Kaplan-Meier. RESULTS: Tumor stages
were distributed as follows: IA, n=2; IB, n=2; IIA, n=6; IIB, n=15;
III, n=17; IV, n=16. Expression of CK20 was detected in 23 of 47
(49%) BM samples. 1-year survival was 20% (median 10 months) in
patients with CK20 expression in BM and 33% (median 12 months)
in patients without (p40.05). CK20 expression was detected in 40
(69%) VB samples with a 1-year survival of 30% (median 12
months), while in patients without survival was 24% (median 11
months) (p40.05). CONCLUSION: More than two-thirds of
patients investigated have systemic dissemination of tumor cells at
the time of diagnosis. However, in the first postoperative year this is
without significance for survival. As most patients had higher tumor
stages, dissemination of tumor cells could be an epiphenomenon of
cancers with advanced stage. However, due the unknown biologic
significance of tumor cell dissemination further studies are required
to elucidate this subject further.
25 CURATIVE OPERATIONS IN PATIENTS WITH
MALIGNANT AMPULLARY TUMORS
Kopchak VM, Khomyak I, Kopchak K, Department of Pancreatic
Surgery, Institute of Surgery and Transplantology, Kiev, Ukraine
INTRODUCTION AND AIM: The problem of proper treatment of
patients with ampullary malignancies is still a challenge for surgeons.
Curative resection is the only effective procedure in the treatment of
patients with this disease. PATIENTS AND METHODS: In the
period 1992–2003, 139 patients with malignant ampullary tumors
were treated in our clinic. There were 80 male patients and 59 female.
Mean age was 57.7 years (range 25–87). All patients underwent
surgical treatment. 79 patients underwent curative surgical resec-
tions, including 35 pancreaticoduodenal resections (PDR): 24
Whipple procedures and 11 pylorus-preserving (PPDR); 44 local
resections (LR): 27 papillectomy and 17 extended papillectomy.
Resectability rate was 56.8%. We performed 11 PPDR, including 2
PPDR with duodenal reconstruction after our technique: we
performed PPDR with the preservation of the distal part of duode-
num; the reconstruction includes step-by-step formation of
pancreatico-jejunal, hepatico-jejunal, proximal and distal duodeno-
jejunal anastomoses with the isolated jejunal loop. RESULTS: 1
patient after died PDR. The postoperative mortality in PDR group
made up 2.9%. Actuarial 5-year survival was 33.4% in the PDR
group, 38.5% in the extended papillectomy group and 52.2% in the
papillectomy group. CONCLUSION: Local resections as more
physiological procedures are indicated in patients with localized
tumors. PPDR with duodenal reconstruction could be indicated in
patients with malignant ampullary tumors, the advantages are
connected with preservation of the function of duodenojejunal
connection.
26 PYLORUS PRESERVATION DOES NOT CONTRIBUTE
TO DELAYED GASTRIC EMPTYING FOLLOWING
PANCREATICODUODENECTOMY
Horstmann O, Ghadimi M, Strohmeyer A, Becker H, Department of
General Surgery, University Clinic Go¨ttingen, Go¨ttingen, Germany
INTRODUCTION AND AIM: DGE has been specifically attrib-
uted to pylorus preservation. As PPPD has been shown to be
comparable to the classical Kausch-Whipple pancreaticoduode-
nectomy (KWPD) in terms of oncological radicality, DGE has
advanced to be the leading argument for hemigastrectomy in PPPD.
PATIENTS AND METHODS: A prospective non-randomized
comparison of patients undergoing PPPD (n=113), KWPD (n=19)
and duodenum-preserving, pancreatic head resection (DPPHR,
n=18) was performed. First, groups were analyzed with regard to
structural similarity; then, they were compared with special emphasis
on DGE and other postoperative complications. Finally, further
prognostic factors were sought that had an impact on DGE.
RESULTS: The PPPD group was comparable to the KWPD group,
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but not to the DPPHR population. The in-clinic course following
DPPHR compared favorably to PPPD as well as KWPD and here no
DGE occurred. The overall morbidity rates of PPPD and KWPD
were comparable (moderate and severe complications in 15% versus
26% and 18% versus 5%, respectively, n.s.); one patient died in
hospital (mortality rate 0.7%). DGE was distributed evenly among
PPPD (12%) and KWPD patients (21%, n.s.) and it was noted
almost exclusively when other postoperative complications were
present (p50.0001). No further prognostic factors influencing DGE
could be identified. CONCLUSION: Pylorus preservation does not
increase the frequency of DGE. DGE almost exclusively occurs as a
consequence of other postoperative complications. Therefore, DGE
should not be used as an argument to advocate hemigastrectomy in
PPPD.
27 THE MANAGEMENT OF CANCER METASTASIZING
TO THE PANCREAS
Barron P, Doumit G, Mimeault R, General Surgery, University of
Ottawa, Ottawa, Canada
INTRODUCTION AND AIM: Patients presenting with a mass in
the pancreas are rarely found to have isolated metastases from a non-
pancreatic primary. The aim of this study was to identify the inci-
dence of such lesions and review management. PATIENTS AND
METHODS: Between 01/04/96 and 01/01/2003 at the Ottawa
Hospital a tertiary care centre associated with University of Ottawa,
388 patients presenting with a localized pancreatic mass (head 314,
body 30, tail 44) causing obstructive jaundice or other abdominal
complaints were identified. Chart review was conducted to detect
instances where the pancreatic mass was found to be a cancer from a
non-pancreatic primary. Patients presenting with pancreatic masses
as part of a spectrum of widely metastatic disease were excluded from
the study. RESULTS: 5 cases of isolated metastatic cancer to the
pancreas were identified; 3 renal cell cancers, 1 breast cancer, and 1
carcinoid tumour. 3 tumours were located in the head of the
pancreas, 1 in the body and 1 in the tail. One patient had two lesions,
one in the head and the other in the tail. One renal cell cancer, the
breast cancer and carcinoid tumour were resected for cure. All
patients are alive at 54, 66, and 84 months, respectively. One renal
cell cancer had invasion of the portal vein and received palliative
radiation treatment only. Another renal cell cancer had significant co-
morbidities and was judged unfit for surgery. The pathological
diagnosis was made following surgery in the resected cases, as it is not
our practice to perform pre-operative biopsy in radiologically
resectable pancreatic lesions. No postoperative adjuvant treatment
was given. CONCLUSION: Our results show that such lesions are
rare but should be suspected in patients with a history of previous
malignancy. If operable, long-term survival may be obtained. An
isolated metastasis to the pancreas from a carcinoid tumour has not
been reported previously.
28 THREE INDEPENDENT FACTORS INFLUENCE
SURVIVAL AFTER CURATIVE RESECTION FOR
PANCREATIC ADENOCARCINOMA
Gulbinas A, Barauskas G, Pundzius J, Department of Surgery,
Kaunas University of Medicine, Kaunas, Lithuania
INTRODUCTION AND AIM: To evaluate long-term survival of
patients surgically treated for pancreatic adenocarcinoma and to
determine independent factors influencing survival. PATIENTS
AND METHODS: Data were prospectively collected from conse-
cutive series of patients resected for pancreatic adenocarcinoma at
Kaunas University of Medicine Hospital during the period 1999–
2004. 110 patients underwent radical resection and postoperative
chemoradiotherapy according to the protocol. Overall survival
probabilities were calculated using the Kaplan-Meier method. All
factors likely to be predictive of survival after pancreatic resection
were evaluated by univariate analysis. Multivariate analysis using
Cox model was completed for all factors with p50.05 at univariate
analysis. RESULTS: Median survival of the patients was
11.2 months. Sex of the patient, preoperative bilirubin levels, intra-
operative blood loss, overall postoperative morbidity, pancreas-
related complications and differentiation grade of the tumor did not
influence survival. Univariate analysis revealed that main factors
influencing survival were age of the patient, stage of the disease,
and tumor invasion into resection surface of pancreas, whereas
multivariate analysis highlighted the T stage, number of metastatic
lymph nodes and age of the patient at the cut-off level of 70 years
as independent factors influencing survival probability. CONCLU-
SION: Survival probability after curative resection for pancreatic
adenocarcinoma was decreased significantly for patients older than
70 years, having higher T stage, and more metastatic lymph nodes.
29 MANAGEMENT OF INFLAMMATORY PANCREATIC
MASSES MIMICKING PANCREATIC CARCINOMA: OUR
EXPERIENCE
Palladino E2, Marino Marsilia G1, Federico R2, Avvisati G2, Aloj G2,
(1) Pathology, AORN A. Cardarelli – Napoli; (2) Surgery, Ospedale
Civile di Torre Annunziata, Torre Annunziata (NA), Italy
INTRODUCTION AND AIM: Pancreatic head cancer represents a
frequent abdominal tumour. However, some cases of benign
inflammatory masses mimicking pancreatic carcinoma have been
reported in the literature. We describe four patients undergoing
surgery for preoperative diagnosis of pancreatic head carcinoma, with
a histology of inflammatory pseudo-tumour, underlining the need for
an aggressive surgical approach. PATIENTS AND METHODS:
Four patients were admitted for pancreatic head mass. All were male,
aged 37–40 years (mean 38.7). Three of four patients had a previous
history of alcohol abuse. Abdominal CT showed a large mass in the
head of the pancreas defined as ‘malignant neoplasm’. Three patients
underwent Whipple procedure, while in a fourth patient a ‘palliative’
Roux-en-Y hepatico-jejunostomy was performed. Patients under-
going Whipple procedure had primary closure of pancreatic stump.
RESULTS: All patients survived surgery, with prompt return to
normal bowel function. Those undergoing Whipple procedure
developed temporary postoperative pancreatic fistula. This resolved
spontaneously from 30 to 90 postoperative day. The patient with
hepatico-jeunostomy alone underwent biopsy intra- and post-
operatively, both specimens giving negative results. Histology in
patients undergoing Whipple procedure was ‘chronic pancreatitis’ in
two cases and pancreatic pseudo-tumour in the third patient.
CONCLUSION: Cases of benign masses in the head of pancreas
mimicking pancreatic carcinoma have often been reported in recent
literature. Preoperative radiological diagnosis has proved unreliable
in our series, as well as in other reported cases. As chronic pancreatitis
is considered an additional risk factor for pancreatic cancer, an
aggressive surgical attitude in cases of preoperative diagnostic
dilemma seems justified.
30 CYSTIC TUMORS OF THE PANCREAS – RADICAL OR
ORGAN-PRESERVING RESECTION?
Siech M2, Thumerer S1, Henne-Bruns D1, Beger HG1, (1)
Department of General Surgery, University of Ulm, Germany;
(2) Ostalb-Klinikum Aalen, General Surgery, Aalen, Germany
INTRODUCTION AND AIM: Cystic tumors comprise only 1% of
all pancreatic tumors. The type of surgical management is presently
under discussion. PATIENTS AND METHODS: Between 1986
and 2004 we treated 101 patients with cystic tumors of the pancreas.
We report the largest European series of a single surgical institution.
Data were documented prospectively and patients’ evaluation was
performed retrospectively. 67% of patients were treated by radical
oncological resection and 32% had an organ-preserving operative
procedure. RESULTS: Hospital mortality was 0%. We observed
tumor recurrence in mucinous entities in 9% after radical and in 13%
after organ-preserving resection (n.s.). Postoperative ‘new’ diabetes
mellitus was 41% significantly higher after radical resections than
after organ-preserving procedure (24%, p50.01). Patients with
mucinous cystadenocarcinoma had a median survival of 36 months.
90% of all patients with borderline or benign cystic neoplasia lived
longer than 36 months. CONCLUSION: In serous cystic lesions and
solid pseudopapillary tumors we recommend organ-preserving
resection. All mucinous cystic tumors are of malignant or borderline
nature and should be treated as such by radical resection.
31 PREOPERATIVE STAGING OF PANCREATIC
CARCINOMA: IS DUAL-PHASE SPIRAL CT ADEQUATE FOR
THE CONFIRMATION OF ITS RESECTABILITY?
Mylona S1, Thanos L1, Georgios S2, Fragiskou N1, Hristofidis T2,
Karaliotas K2, Batakis N1, (1) Radiology, Red Cross Hospital; (2)
Surgical, Red Cross Hospital, Athens, Greece
INTRODUCTION AND AIM: To present the value of dual-phase
spiral CT for the confirmation of resectability and preoperative
staging of pancreatic carcinoma. PATIENTS AND METHODS: In
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a period of 4 years 184 patients with pancreatic carcinoma underwent
dual-phase spiral CT for preoperative staging. CT scans after IV
administration of contrast material with an electronic injector were
obtained at the arterial (scan delay=20 s) and at the portal venous
phase (scan delay=50 s) under a protocol with total volume=
150 ml, flow rate 5 ml/s. We correlated the CT findings with surgi-
cal-pathologoanatomic findings. RESULTS: Dual-phase spiral CT
was positive for pancreatic carcinoma at 178 patients (96.7%). In 6
patients results were false-positive (3.3%). 44 (78.4%) of 55 patients
showed hepatic metastases, 33 (64.7%) of 51 patients showed lymph
node enlargement, 49 (88%) of 60 patients had vascular invasion and
8 (66.6%) of 12 patients had peritoneal metastases. The accuracy of
the method was up to 90%. CONCLUSION: Dual-phase spiral CT
is a safe, noninvasive, and accurate method to investigate pancreatic
carcinoma and should be considered as the standard preoperative
method for assessing lesion resectability.
32 PROGNOSTIC VALUE OF P27KIP1 EXPRESSION IN
ADENOCARCINOMA OF THE PANCREATIC HEAD REGION
Polkowski WP2, Skomra D1, Stanis3awek A2, Kurylcio A2, Mielko J2,
Wierzbicki R2, Budny W2, Lewicka M2, Korobowicz E1, (1)
Department of Clinical Pathology; (2) Department of Surgical
Oncology, Medical University of Lublin, Lublin, Poland
INTRODUCTION AND AIM: p27kip1 (p27) is a tumour
suppressor gene, functioning as cyclin-dependent kinase inhibitor,
and independent prognostic factor in breast, colon, and prostate
adenocarcinomas. Conflicting data are reported for adenocarcinoma
of the pancreas. The aim of the study was to establish the prognostic
value of p27 expression in adenocarcinoma of the pancreatic head
region. PATIENTS AND METHODS: The study included 45
patients (male/female ratio 2 : 1; mean age 59, range 38–82 years)
with adenocarcinomas of the pancreatic head region: 27 pancreatic
head, 13 ampullary, and 5 distal common bile duct. All patients
underwent Kausch-Whipple pancreatoduodenectomy (n=39),
pylorus-preserving pancreatoduodenectomy (n=5), or nearly total
pancreatectomy (n=1). Eight patients received adjuvant chemo-
therapy postoperatively. Follow-up time was 3–60 months. Tumours
were staged according to the pTNM classification (UICC 1997).
Immunohistochemistry was done on paraffin-embedded blocks from
tumour sections. Quantitative determination of p27 expression was
based on the proportion of p27-positive cells (510%=negative).
Pearson test, survival analysis using the Kaplan-Meier method and
the log-rank test were used. RESULTS: Positive p27 expression was
detected in 21 tumours (45.7%), whereas 24 tumours (53.3%) were
p27-negative. There were no significant correlations between p27
index and stage, lymph node involvement, or completeness of
tumour removal (R0 vs R1/R2). Median survival time in patients with
p27-positive tumours was 25 months, whereas in patients with p27-
negative tumours it was 30 months (p=0.73). Even when analysis
was stratified according to ampullary and non-ampullary carcino-
mas, the survival comparison of patients with p27-positive and
-negative tumours did not reveal significant differences.
CONCLUSION: p27kip1 expression has no prognostic value in
patients following resection for adenocarcinoma of the pancreatic
head region.
33 FAST-TRACK MANAGEMENT OF PATIENTS
UNDERGOING PROXIMAL PANCREATIC RESECTION
French JJ, Mansfield S, Jacques K, Jacques B, O’Sullivan C, Manas
D, Charnley R, Department of Surgery, Freeman Hospital,
Newcastle upon Tyne, UK
INTRODUCTION AND AIM: Fast-track surgical treatment, with
resection before biliary drainage, of jaundiced patients with proximal
pancreatic/periampullary malignancy could reduce the number of
biliary drainage procedures and their attendant complications. We
evaluated this approach in patients treated over a 6-month period.
PATIENTS AND METHODS: Between 1-04-04 and 30-09-04,
based on their presenting bilirubin levels and other logistical factors,
jaundiced patients who might be suitable for fast-track management
were identified. Data on complications and hospital stay were
compared with those patients in whom a conventional pathway (with
biliary drainage) was used during the same time period. Data were
also compared with a group of patients from the preceding 6 months
(1-10-03 to 30-9-04). RESULTS: Six patients were fast-tracked and
12 patients were treated in the conventional pathway. Fast-track
patients median (range) serum bilirubin level (micromol/l) was 310
(162–391) at time of the operation. Median (range) of time from
referral to operation, 14 days (6–33) vs 42 (26–126), was significantly
shorter in fast-track patients vs conventional patients. Length of
hospital stay at 18 days (11–28), surgical complications and mortality
in fast-track patients were similar to those for conventional patients.
Prior to surgery the 12 conventional patients underwent a total of 25
biliary drainage procedures resulting in 3 major complications.
Comparison with the group of patients from the previous time period
indicated that the conventional group were not disadvantaged.
CONCLUSION: Fast-track management of patients with distal
biliary strictures is safe and gives clear benefit in terms of reducing
the waiting time to surgery and the number of biliary drainage
procedures per patient.
34 PHASE III TRIAL CAPRI (ADJUVANT
CHEMORADIOIMMUNOTHERAPY OF PANCREATIC
ADENOCARCINOMA) VERSUS 5-FU ALONE
Schmidt J1, Ma¨rten A1, Schmitz H1, Lindel K2, Goldschmidt H3,
Herrmann T3, Stremmel W3, Ho A3, Debus J2, Diehl V4, Bu¨chler
M1, (1) Department of Surgery; (2) Department of Radiology; (3)
Department of Internal Medicine; (4) NCT, University of
Heidelberg, Heidelberg, Germany
INTRODUCTION AND AIM: Carcinoma of the exocrine pancreas
has an especially poor prognosis. The 5-year survival for all stages is
51% with a median survival of 4–6 months. Even after surgical
intervention with a curative intention the 2-year survival is only 25%.
PATIENTS AND METHODS: We initiated this summer a phase
III trial where we compare chemoradioimmunotherapy (CapRI) with
5-FU plus folinic acid, i.e. the best arm of the first large European
randomised ESPAC-1 trial. Primary objective is the overall survival
in both arms. Secondary objective is to evaluate the role and the
mechanism of interferon alpha 2b in patients’ chemoradiation regi-
men, to assess the toxicity, the disease-free interval, the quality of life
and to test different factors for their potential role as predictive
markers. A total of 110 patients with R0 or R1 resected pancreatic
adenocarcinoma will be enrolled. Recruiting phase should be
finished after 1 1=2 years. With a follow-up of 2 years a total running-
time of approx. 3 1=2 years should be expected. RESULTS: The
chemoradioimmunotherapy protocol is based on results from a phase
I/II trial from the Virginia Mason Clinic. They have recently
published data of postoperative cisplatin, 5-fluorouracil, interferon
alpha-2b, and external-beam radiation administered following
pancreaticoduodenectomy. They have treated 43 patients with
mainly stage III tumors. 84% had positive lymph nodes and 19% had
positive cut margins. After a mean follow-up of 31.9 months, 67% of
the patients were still alive. Actuarial overall survival for the 1-, 2-,
and 5-year survival rates were 95%, 64%, and 55%, respectively.
35 CURRENTMANAGEMENTOF PANCREATIC CANCER:
HOW EFFECTIVE IS IT?
Spicak J4, Benes M4, Pafko P1, Leffler J2, Kral V3, (1) Surgery III,
University Hospital Motol; (2) Sugery I, University Hospital Motol;
(3) Surgery I, University Hospital Olomouc; (4) Department of
Hepatology and Gastroenterology, IKEM, Prague, Czech Republic
INTRODUCTION AND AIM: Effective treatment of pancreatic
cancer is dependent on correct and early diagnosis and staging. The
aim of our multicentric study was to determine whether or not the
diagnostic process is rational, uniform, and if correct diagnosis and
staging are reflected in effective treatment. PATIENTS AND
METHODS: We retrospectively analyzed initial symptoms, length
of the diagnostic process, use of imaging methods and their algo-
rithm, and the use of individual therapeutic methods in four centers
specializing in hepato-pancreato-biliary surgery. RESULTS: The
most frequent first symptom was dyspepsia in 35 patients followed by
pain in 33 and jaundice in 24. Radical resection was performed in 24
patients, exploratory laparotomy in 14, palliative surgery in 35 and
chemotherapy in 14 patients. Mean time from the onset of the first
symptoms to presentation (time I) was 32+28 days. Mean time of
the diagnostic process to specific treatment (time II) was 3.1+3.2
months (1–24 months). Mean time I in patients presenting with
dyspepsia was 44.1+25.7 days, in patients presenting with jaundice
or pain 30.0+27.8, and in those who underwent resection
26.5+24.1 days. Mean time II in these groups was 3.7+4.4,
2.8+2.2, and 2.1+1.5 months, respectively. Ultrasound was the
most frequently used imaging method (160 cases) followed by CT
(116), ERCP (103), endosonography (30), and MR (7). The mean
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number of diagnostic procedures per patient was 4.3+1.6. Fine
needle biopsy was performed in 16 patients. The most frequent
algorithm of imaging methods was ultrasound followed by ERCP and
CT. CONCLUSION: The process of establishing the diagnosis of
pancreatic cancer is not uniform and the imaging methods are used
abundantly. The decision-making process undertaken preoperatively
is not sufficient, as reflected by the inadequately high rate of
explorations in cases when radical resection could not be performed.
Despite the immediate availability of all imaging modalities, the
process of diagnosis in pancreatic cancer is long depending on the
first symptoms, which can influence resectability. In resected
patients, the process of diagnosis was significantly shorter.
36 A CASE OF OSTEOCLAST-LIKE GIANT CELL TUMOR




Cho CK1, Koh YS1, Kim JC1, Kim HJ1, Park CH2, Joo YE2,
Lee WS2, Rew JS2, Kim SJ2, Jeong YY3, (1) Department of Surgery;
(2) Department of Internal Medicine; (3) Department of Radiology,
Chonnam National University Medical School, Gwangju, Korea
INTRODUCTION AND AIM: Osteoclast-like giant cell tumor of
pancreas (OGTP) is a very rare neoplasm and its clinical behavior
and histiogenesis are still controversial. Recently we experienced a
case of OGTP with ductal adenocarcinoma resected surgically, so
herein we report the case with the results of histopathological,
immunohistochemical (IHC), ultrastructural and molecular bio-
logical studies. PATIENTS AND METHODS: The patient was a
63-year-old woman who underwent operation for resection of
pancreas tumor. The performed operation procedure was en bloc
excision of mass with distal pancreatectomy and splenectomy, left
adrenalectomy, partial resection of gastric upper body, tumor
thrombectomy in splenic vein. We examined the resected tumor by
microscopic examination, IHC study, electron microscopy (EM),
and molecular biological studies of K-ras gene analysis. RESULTS:
In microsopic findings, the tumor is composed of typical ductal
adenocarcinoma and surrounding mononuclear cells (MNC) inter-
mingled with osteoclast-like giant cells (OGC) and pleomorphic
large cells. In the IHC study, ductal adenocarcinoma cells are posi-
tive for cytokeratin and EMA, and OGC are strongly positive for
CD68. MNC are positive for CD68 and lysozyme, and pleomorphic
large cells are strong positive for vimentin. In EM findings, promi-
nent nucleoli with dispersed clumps of heterochromatin and the
cytoplasm containing ample mitochondria, moderate amount of
rough ER without evidence of epithelial differentiation were observed
in MNC. In OGC, multiple nuclei with dispersed chromatin and
fine chromatin rim, and cytoplasm characterized by abundant
mitochondria with variable size, free ribosome, dilated empty rough
ER. In analysis of K-ras gene mutation, there was no mutation at
codon 12–13 in ductal adenocarcinoma cells, MNC and OGC.
CONCLUSION: We report a case of OGTP with ductal adeno-
carcinoma focusing on histopathological, IHC, ultrastructural and
molecular biological studies. In the present case, OGC and MNC
were different in origin from ductal cells and suggested to be non-
neoplastic and mesenchymal in origin.
37 EARLY AND LATE OUTCOME AFTER
PANCREATICODUODENECTOMY FOR CANCER IN THE
ELDERLY
Scurtu R, Jaeck D, Oussoultzoglou E, Rosso E, Bachellier P, Weber
JC, Centre de Chirurgie Visce´rale et de Transplantation, CHU
Hautepierre, Strasbourg, France
INTRODUCTION AND AIM: Radical surgery is the only valid
treatment for pancreatic cancer and for periampullary tumors. Before
the early 1990s pancreaticoduodenectomy was not recommended in
patients over 70 years because of associated high mortality and
morbidity. Currently, increased experience, advances in periopera-
tive care and better patient selection have reduced the mortality
and morbidity rates after pancreaticoduodenectomy. Therefore
pancreaticoduodenectomy has been performed in patients over 70
and even 75 years with acceptable results. The aim of this study was
to identify if there is any threshold in patients’ age over which
pancreaticoduodenectomy would be deleterious. PATIENTS AND
METHODS: From June 1995 to October 2003, 70 elderly patients
(range 70–84 years) underwent pancreaticoduodenectomy for
cancer. 38 patients were younger than 75 years (group A) and 32
(group B) were older. Postoperative morbidity, mortality, length of
hospital stay, overall and disease-free survival were analyzed.
RESULTS: Patients from both groups had similar characteristics
and were identically managed. There were no statistical differences
between the recorded postoperative mortality, morbidity, mean
length of hospital stay in the two groups of patients. The mean overall
survival was similar in both groups (15 months) and it was signifi-
cantly influenced only by the histological tumor type, with the
worst results in patients with pancreatic adenocarcinoma.
CONCLUSION: Outcomes after pancreatoduodenectomy in
patients over 75 years old do not differ from those recorded in
younger patients. It appears that there is no threshold in patients age
contraindicating pancreaticoduodenectomy. Overall survival is
influenced only by the tumor pathology type.
38 A RETROSPECTIVE STUDY OF MALIGNANT TUMOR
OF THE PANCREAS AND PERIAMPULLARY AREA
Ota AS, Andraus D, Machado A, Azevedo G, Correia M, Ribeiro FS,
Fernandes B, General Surgery, Hospital Geral de Bonsucesso, Rio de
Janeiro, Brazil
INTRODUCTION AND AIM: Mostly, patients with periampullary
cancers are diagnosed at a stage in which curative resection is not
possible. The aim of this study was to present our experience, diag-
nostic possibilities and treatment of periampullary tumors, especially
tumors in advanced stage at the time of the diagnostic – patients
presenting with 430 days of progressive obstructive jaundice, high
total billirubin and albumin levels 53 mg/dl. PATIENTS AND
METHODS: In the period January 2003 to October 2004, 46
patients with periampullary tumor were studied retrospectively. The
diagnosis was established by transabdominal ultrasonography and
CT. In 27 men (59%) and 19 women (41%) the mean age was 58.9
years old (28–86 years). RESULTS: Among these patients, 54% had
a pancreatic ductal carcinoma. Procedures were performed in all
patients, of which 17 (37%) were duodenopancreatectomies. The
mortality rate in the group undergoing Whipple procedure was 35%
(6 patients), and the mortality rate for all patients was 37% (16
patients). The average length of hospital stay was 30.7 days (6–112
days). Variables analyzed in this study included sex, age, procedure
performed, histopathology, mortality, reoperation and survival.
CONCLUSION: In recent years, surgery has been considered the
gold standard of therapy because new technologies are able to reduce
morbility and mortality. In very advanced neoplasia, palliative
surgical care permits better survival and quality of life.




Rosso E, Jaeck D, Oussoultzoglou E, Scurtu R, Bachellier P,
Weber JC, Centre de Chirurgie Visce´rale et de Transplantation,
CHU Hautepierre, Strasbourg, France
INTRODUCTION AND AIM: Lymph nodes and tumor char-
acteristics were considered the most important prognostic factors for
survival after curative resection for ampullary carcinoma (AC). The
aim of the study was to determine whether performing a PD with
extended retroperitoneal lymphadenectomy (ERL) improves survi-
val in patients with AC. PATIENTS AND METHODS: Between
July 1994 and November 2002, 24 patients underwent curative PD
with standard or ERL for AC in our institution. Surgical outcome,
long-term and disease-free survival of patients undergoing a standard
lymphadenectomy (n=10; group A) or ERL (n=14; group B) were
compared. RESULTS: Patients and tumor characteristics were
similar. Postoperative mortality and overall morbidity did not differ
between groups A and B. The median follow-up was 25 months. The
5-year overall survival rates were 46.7% in group A and 36.7% in
group B. Univariate analysis showed that tumor size 435 mm;
p=0.004), number of metastatic lymph nodes (43; p=0.001) and
ratio of positive lymph nodes/total nodes resected (40.30; p=0.001)
significantly alter overall and disease-free survival. 5-year survival for
patients with small AC and 53 positive lymph nodes was 50.6%,
while no 3-year survival was recorded for patients with 43 positive
lymph nodes or AC435 mm (p=0.001). CONCLUSION: Lymph
node status significantly influences survival. PD with ERL seemed to
be justified to allow a better staging of the disease.
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40 PALLIATIVE PROCEDURES FOR PANCREATIC
CANCER
Ryska M, Belina F, Strnad R, Surgery Department, Central Military
Hospital, Prague 6, Czech Republic
INTRODUCTION AND AIM: The only chance of prolonged
survival of patients with pancreatic cancer is radical tumour resec-
tion, but pancreatic cancer proves to be resectable in only about
10–20%. Efforts to improve the patient quality of life lead to palliative
procedures. PATIENTS AND METHODS: We have performed
162 surgical procedures for pancreatic cancer from May 1998 to
October 2004. 73 of them were palliative: in 63 patients biliodigestive
anastomosis (38 males and 25 females with median of age 66 years)
and in10 palliative resections (5 males and 5 females with median of
age 57 years). RESULTS: Palliative bypass: 57 biliodigestive
anastomosis and 20 gastroenteroanastomosis were performed. 20
patients developed early complications: wound infection 7, cardial
complication 3, pulmonary infection 3, intra-abdominal abscess 2,
billiary leak 1, acute pancreatitis 1, others 10. Three patients died
in the early postoperative course from heart failure and cancer
progression. Palliative resection: 8 patients underwent proximal
duodenopancreatectomy and 2 left pancreatectomy. 5 patients
developed early complications: intra-abdominal abscess in two
patients pancreatic leak, acute postoperative pancreatitis and
bronchopneumonia in one case. Two patients died in the early
postoperative course from acute pancreatitis and pancreatic leak. 12
(resp. 24, 30) months survival rate in the palliative resection
group compared to the bypass procedures was 30%: 21%, 30%: 10%
and 15%: 8% respectively (p50.05). There were no significant
differences in survival rate between the two groups using Kaplan-
Meier survival curve. CONCLUSION: We have found the statistical
difference in survival between the radical and palliative groups. There
were no significant differences in patient survival between two groups
for palliative resection and biliodigestive bypass.
41 OBSTRUCTIVE JAUNDICE IN VON
RECKLINGHAUSEN DISEASE – COINCIDENCE OR
CORRELATION?
Yeluri SV, Madhok B, Kapoor A, Dadayal G, Duttaroy D,
Department of Surgery, SSG Hospital and Medical College,
Baroda, India
INTRODUCTION AND AIM: The occurrence of a triad of von
Recklinghausen disease (VRD), periampullary neoplasm and
intestinal neurofibromas in the same patient is uncommon. The aim
of this paper is to report such a case, review and analyze literature
behind this rare association and to establish a positive causal link
between these three conditions. PATIENTS AND METHODS:
This is a case report and review of literature, from a university
hospital setting, of an elderly female patient with VRD who under-
went pancreato-duodenectomy with resection of proximal jejunum
for a periampullary neoplasm, with multiple neurofibromas and a
neurofibrosarcoma in the proximal jejunum. RESULTS: Review of
the literature suggests that patients with VRD are at an increased risk
of developing periampullary neoplasms of neural crest and non-
neural crest origin. Carcinoid tumours are the most common form of
periampullary tumours associated with VRD. A quarter of all patients
with VRD have gastrointestinal involvement in the form of neuro-
fibromas, ganglioneuromas, paragangliomas and neurilemmomas,
most commonly located in the distal ileum, with a 10–15% risk of
malignant transformation. CONCLUSION: A strong clinical
suspicion should be maintained for gastrointestinal symptoms in any
patient with VRD. We emphasise a multimodal, intense and
complete diagnostic and therapeutic approach in all patients with
VRD presenting with abdominal symptoms.
42 SYNCHRONOUS DOUBLE CANCERS OF THE
STOMACH AND PANCREAS: REPORT OF A CASE
Ota AS, Machado A, Balieiro M, Motta C, Silva R, Fernandes B, Sa´
Ribeiro F, General Surgery, Hospital Geral de Bonsucesso, Rio de
Janeiro, Brazil
INTRODUCTION AND AIM: Multiple primary cancers generally
fall into two categories: (1) synchronous, in which the cancers occur
at the same time; and (2) metachronous, in which the cancers follow
in sequence. Unfortunately, detection of second or later primaries
often relies on the degree of post treatment surveillance, influencing
the prognosis and altering consequences. This study describes a case
of double cancers in which cancer of pancreas was associated with
carcinoma of the stomach. PATIENTS AND METHODS: We
present here the case of a 72-year-old man who developed synchro-
nous double cancers of pancreas and stomach. The patient was
referred to our hospital in January 2004, with a provisional diagnosis
of pancreatic tumor. Abdominal CT scan revealed a mass in
pancreatic head, and upper digestive endoscopy did not reveal any
alteration. A laparotomy was performed and gastroduodeno-
pancreatectomy was carried out. RESULTS: The patient was
subsequently diagnosed as having double carcinoma of the stomach
and pancreas. The histologic sections showed a moderately differ-
entiated adenocarcinoma from the pancreatic head, whereas those
from the stomach showed a poor differentiated signet ring cell
adenocarcinoma infiltrating until submucosa. CONCLUSION:
Pancreatic carcinoma carries a poor prognosis, especially invasive
carcinoma of the pancreas. Double carcinoma in this association is
rare and prognosis depends on the pancreatic carcinoma.
43 SOLID PSEUDOPAPILLARY NEOPLASM OF THE
PANCREAS
Chatzitheoklitos E1, Katsourakis A1, Farmakis D1, Kechagia T2,
Karagianopoulou G3, (1) Surgery, Agios Dimitrios, General
Hospital; (2) Pathology, Agios Dimitrios, General Hospital;
(3) Pathology, University of Thessaloniki, Thessaloniki, Greece
INTRODUCTION AND AIM: Solid pseudopapillary neoplasm
(SPN) is a rare tumor of the pancreas that frequently occurs in young
females. SPN is a low grade malignant tumor that may evolve years
before symptoms start. The pathogenesis of the tumor remains
unclear and there are no adequate reports to evaluate the manage-
ment and the long-term control of the neoplasm. However, radical
resection should be considered the therapy of choice. PATIENTS
AND METHODS: We describe a new case of SPN which occurred
in a 36-year-old female who complained of lumbar pain and episodic
mild abdominal pain, with a history of cholecystectomy 10 years ago,
cystic changes of right breast, mitral valve prolapse and iron defi-
ciency anemia. The tumor mass detected by ultrasound, MRI, CT.
The diagnosis was confirmed after all the appropriate histological
tests. RESULTS: The tumor was localized at the neck of the
pancreas. The preoperative diagnosis was uncertain and distal
pancreatectomy with preservation of the spleen was performed. The
patient remains free of symtoms. In the immunohistochemical tests
the neoplastic cells were positive for vimentin, neuron-specific
enolase, chymotrypsin, a-1-antitrypsin, CD-10, CD-56, with
expression of progesterone receptors and mild positivity to chromo-
granin, CD-19-9, cytokeratins 18 and AE1/AE3. CONCLUSION:
SPN has good prognosis and radical resection, where technically
feasible, should be considered the therapy of choice as it provides safe
and effective control of the disease.
44 COMPLICATIONS FOLLOWING PANCREATICO-
BILIARY SURGERY – AN AUDIT
Palep JH, Mehta SS, Khithani AS, Shetty TS, Joshi RM, General
Surgery, LTM Medical College & General Hospital, Mumbai, India
INTRODUCTION AND AIM: An audit of the existing practices in
the surgical management of pancreatico-biliary disorders in a surgical
unit was undertaken to identify the various complications and the
procedure-related morbidity and mortality. PATIENTS AND
METHODS: A prospective analysis of 258 consecutive cases oper-
ated for benign and malignant pancreatico-biliary disorders over a
5.5-year period between February 1999 and August 2004 was carried
out. Each of the postoperative complications were carefully enlisted
and analysed. RESULTS: The various surgeries were grouped under
four broad categories, i.e. surgery for benign CBD pathologies
(n=87), surgery for benign pancreatic pathologies (n=41) as well as
Whipple’s pancreaticoduodenectomies (n=98) and palliative bypass
procedures for malignancy (n=32). Procedure-related morbidity in
the four groups was 18%, 15%, 41% and 31%, respectively, while the
30-day mortality was 0, 1%, 7% and 3%, respectively. CONCLU-
SION: Audit of the current surgical practices highlighted deficiencies
at some levels compared with evidence-based guidelines, although
the results are not unexpected in the Indian context in the setting of a
public hospital. It remains to be seen whether new measures to aid
compliance with protocols will result in improvement in morbidity
and mortality.
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45 FAST-TRACK PANCREATIC SURGERY
Wichmann M, Bruns C, Brandenburg F, Jauch KW, Surgery,
University of Munich-Großhadern, Munich, Germany
INTRODUCTION AND AIM: Surgery of the pancreas is a major
abdominal procedure leading to a number of pathophysiological
alterations during the early postoperative period. Novel approaches
to perioperative care including shortened preoperative starving
periods, preoperative glucose load, sophisticated pain management
and early enteral feeding have resulted in major improvements of
surgical results after major colorectal surgery. These alterations of
perioperative care have been introduced to visceral surgery as
so-called fast-track surgery or multimodal rehabilitation. So far it is
not known whether or not these approaches can also be applied in
pancreatic cancer surgery. PATIENTS AND METHODS: To study
this, a prospective non-randomized clinical study was launched
investigating the potential beneficial effects of fast-track perioperative
care on clinical outcome parameters (complication rates, re-opera-
tion rates, time to demission) as well as physiological alterations
(glucose tolerance) and immune function (lymphocyte subpopula-
tions, circulating interleukins) during the perioperative period of
patients undergoing elective pancreatic cancer surgery. Patients
recruited for this prospective study receive clear carbohydrate-rich
fluid until 2 h before surgery. Bowel preparation is reduced to one
administration of a laxative and pain treatment consists of thoracic
epidural analgesia in combination with COX-II inhibitors. Intra-
operative fluid administration is restricted to 500 ml of colloids and
500 ml of electrolytes. Oral food intake starts on the day of surgery
with clear fluids and is increased to a small amount of solid food on
day 3 after surgery. Complete enteral nutrition is initiated on day 5
after surgery, following opaque media examination of the upper
gastrointestinal tract. Demission from hospital is planned on day 10
after surgery. RESULTS: This prospective clinical study aims to
introduce a novel and successful perioperative care regimen into the
surgical treatment of pancreatic cancer. Major goal is the improve-
ment of postoperative rehabilitation, including glucose tolerance,
mobilization and immune function. CONCLUSION: The feasibility
of fast-track pancreatic surgery as well as clinical and immunological
results of the recently launched study will be presented.
46 NO EVIDENCE OF HELICOBACTER SPECIES IN
PERIAMPULLARY TUMORS BY LIGHT MICROSCOPY
Ozden I2, Gulluoglu M1, Bilge O2, Tekant Y2, Acarly´ K2, Alper A2,
Ary´ogul O2, Dizdaroglu F2, Emre A2, (1) Pathology, Istanbul
University-Istanbul Faculty of Medicine; (2) General Surgery-
Hepatopancreatobiliary Surgery Unit, Istanbul University-Istanbul
Faculty of Medicine, Istanbul, Turkey
INTRODUCTION AND AIM: Epidemiologic studies and investi-
gations on tumor tissues with polymerase chain reaction assays
implicateHelicobacter species as a risk factor for pancreatic and biliary
carcinomas. However, in contrast with gastric carcinomas, the
presence of bacteria in these tumors has not been confirmed by direct
methods. A light microscopic study was performed to investigate the
possible presence of Helicobacter species in periampullary tumors.
PATIENTS AND METHODS: The charts and surgical specimens
of 25 patients who underwent pancreatoduodenectomy (10
pancreatic head carcinomas, 9 distal common bile duct carcinomas,
4 ampulla vateri tumors and 2 duodenal carcinomas) between
December 2002 and May 2004 were evaluated retrospectively. The
presence of Helicobacter species in tumor tissues was investigated by
light microscopy after hematoxylin-eosin, modified Giemsa, and
immunohistochemical staining. RESULTS: Helicobacter species
were not detected in any of the tumors by the three methods.
CONCLUSION: The results of this study do not support a local role
of Helicobacter species in the development of periampullary tumors.
47 PANCREATICODUODENECTOMY: CASE REVIEW
AND DESCRIPTION OF SAFE SURGICAL TECHNIQUE
Machado A, Ota AS, Ribeiro FS, Motta C, Fernandes B, General
Surgery, Hospital Geral de Bonsucesso, Rio de Janeiro, Brazil
INTRODUCTION AND AIM: This survey was carried out by the
first surgical clinic of the Hospital Geral de Bonsucesso, which is the
largest hospital of the public health network in Rio de Janeiro and
reference for the management of cancer, transplantation and emer-
gency medicine. The purpose of this paper is to analyze the indica-
tions for pancreaticoduodenectomy, and describe the surgical
technique employed and its complications. PATIENTS AND
METHODS: Retrospective analysis including 18 patients submitted
to pancreaticoduodenectomy in the timespan from January 2003 to
October 2004. The surgical technique employed was gastro-
pancreaticoduodenectomy. RESULTS: The pancreatic-enteric
anastomosis was performed in an end-to-side fashion with two layers:
the first one binds the pancreatic duct to the enteric mucosa, and the
second one binds the enteric wall to the pancreatic capsule. A
catheter was inserted into the pancreatic duct and its other tip was
externalized through the abdominal wall. The biliary-enteric
anastomosis was made in an end-to-side fashion with placing of a T-
tube through it. This drain was also externalized through the
abdominal wall, by a Witzel procedure. The most common etiology
was pancreatic head neoplasia. Pyloric preservation was performed in
3 patients. There were 7 deaths, which were associated with cardi-
ovascular complications. There was one biliary fistula with benign
behavior. CONCLUSION: Our survey shows patients whose general
state was compromised by periampullary neoplasia, under-
nourishment, anemia and several comorbidities. Nevertheless, the
surgical technique employed proved to be safe, bringing down the
complication rate in critical patients.
48 THE LEUKOTRIENE RECEPTOR BLT2: A KEY PLAYER
IN PANCREATIC CARCINOGENESIS AND A SPECIFIC
MARKER FOR PANCREATIC INTRAEPITHELIAL
NEOPLASTIC LESIONS (PANINS)?
Hennig R3, Ding XZ1, Tong WG1, Yokomizo T2, Bu¨chler MW3,
Friess H3, Rao S4, Talamonti MS1, Bell RH1, Adrian TE5, (1)
Surgery, Northwestern University, Chicago, IL, USA; (2)
Biochemistry and Molecular Biology, University of Tokyo, Tokyo,
Japan; (3) Surgery, University of Heidelberg, Heidelberg, Germany;
(4) Pathology, Northwestern University, Chicago, IL, USA; (5)
Surgery and Pathology, Northwestern University, Chicago, IL, USA
INTRODUCTION AND AIM: Pancreatic cancer has an abysmal
prognosis. Targets for early detection, prevention, and therapy are
desperately needed. As the 5-lipoxygenase pathway is important for
pancreatic cancer development, we examined the expression of the
receptors (BLT1R and BLT2R) for its downstream metabolite,
leukotriene B4. PATIENTS AND METHODS: Receptor expres-
sion was examined in pancreatic cancer cell lines (real-time RT-PCR
and Western blot) and tissues (immunocytochemistry). S2-013 cells
were stably transfected with BLT1R, BLT2R or empty vector to
study the impact on proliferation. RESULTS: BLT1 and BLT2
receptors were expressed (mRNA and protein level) in all pancreatic
cancer cell lines. BLT1R were expressed in cancer cells from 10/10
human pancreatic cancers, and islets from these tissues, 7/7 tissues
from the resection margins, and 8/9 chronic pancreatitis (CP). No
BLT1R staining was seen in PanIN lesions or in 10 pancreatic tissues
from multi-organ donors. In contrast, BLT2R were markedly up-
regulated in PanINs (7/10 cancer tissues and 1 CP tissue with a
PanIN 1b) but not in PanIN 1a lesions or normal ductal cells (9 CP
tissues did not stain for BLT2R). Infiltrating tumor cells were
strongly positive for BLT2R in cancers and lymph node metastases.
Overexpression of BLT1R significantly increased cell proliferation,
while overexpression of BLT2R significantly inhibited growth.
CONCLUSION: Leukotriene B4 receptors (BLT1R and BLT2R)
are overexpressed in human pancreatic cancer. However, BLT2
receptors are already up-regulated in PanINs and their over-
expression in tumor cells inhibits growth. BLT2 receptors are an
early specific marker and a possible new target for chemoprevention
or therapy of pancreatic cancer.
49 INTRADUCTAL PAPILLARY MUCINOUS NEOPLASMS
(IPMNS): MANAGEMENT OF THE PANCREATIC MARGIN
AND RECURRENCE. THE UNIVERSITY OF VERONA
EXPERIENCE
Crippa S1, Salvia R2, Valli L1, Bassi C1, Falconi M1, Muselli P1,
Pederzoli P1, (1) General Surgery, University of Verona, Verona,
Italy; (2) Azienda Ospedaliera di Verona, General Surgery,
Verona, Italy
INTRODUCTION AND AIM: IPMNs originate from the
pancreatic duct epithelium and can potentially involve the entire
main duct. Histology may range from mild dysplasia to invasive
carcinoma. The aim of this study is to determine local recurrences
after resection and to correlate them with the histology. PATIENTS
AND METHODS: We analysed histology, pancreatic margins, and
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recurrence rates of 127 patients (70 male, 57 female, mean age 63,
range 34–83) affected by IPMN who underwent surgical resection in
our institution from 1990 to June 2004. RESULTS: 27 patients
(21.3%) had adenoma, 37 (29.1%) borderline tumours, 13 (10.2%)
in situ carcinoma and 50 patients (39.4%) had invasive carcinoma. 14
patients underwent total pancreatectomy while 113 underwent
partial pancreatectomy; in this group resection margins were negative
in 73 patients (64.6%), positive for adenoma in 15 (13.3%), positive
for borderline in 16 (14.2%), positive for carcinoma in 1 case (0.9%)
and with epithelial denudation in 8 cases (7%). Local recurrence was
observed in 7 cases (6.2%), after a mean time of 51.4 months (range
37–62). After the first resection 5 patients had IPMIC and 1 IPMC,
in the resection margins moderate dysplasia (n=4) and epithelial
denudation (n=2) were present; the seventh had an IPMA with
negative resection margin. In the latter case progression was
observed, actually he showed IPMC after the second operation.
CONCLUSION: Local recurrence even with a ‘positive’ resection
margin appears to be more related to the final histology than the
pancreatic margin. Because of the long-term disease progression we
need to follow the patients up for a longer time.
50 PEPTIDE RECEPTOR RADIONUCLIDE THERAPY IN
ENDOCRINE TUMORS OF THE PANCREAS
Nieveen van Dijkum EJ3, De Herder W1, Kwekkeboom D2,
Krenning E2, van Eijck C3, (1) Internal Medicine; (2) Nuclear
Medicine; (3) Surgery, Erasmus MC, Rotterdam, The Netherlands
INTRODUCTION AND AIM: Endocrine pancreatic tumors are
known to have somatostatin receptors (SS-Rs), especially subtype
SST2 and SST5. Octreotide has a high affinity for SST2 and radio-
labeled octreotide is used in an octreoscan to diagnose endocrine
tumors. The aim of the present study was to assess if radiolabeled
177Lu-DOTA0-Tyr3 Octreotate, can also be used in a higher dose
as peptide receptor targeted radiotherapy. PATIENTS AND
METHODS: A single-center prospective study including patients
with metastatic or locally advanced endocrine pancreatic tumors was
performed. Exclusion criteria were little uptake at the octreoscan, Hb
56 mmol/L, WBC 52*109/L, platelets 580*109/L, creatinine
clearance540 ml/min or a Karnofsky score550. Patients received a
cumulative dosage of 750–800 mCI through 177Lu-DOTA0-Tyr3
Octreotate. Toxicity of the therapy was evaluated. Follow-up was
performed with routine blood tests, chromogranin-A levels and CT
or MRI. The tumor response was measured with CT or MRI using
Southwest Oncology Group (SWOG) solid tumor response criteria.
RESULTS: A total of 42 patients with neuroendocrine pancreatic
tumors was included. Two patients died before receiving their final
dose. Toxicity was low, with vomiting in 14%, mild nausea in 30%,
hair loss in 45% of the patients and stable haematology and kidney
function. Complete response after 3 months occurred in 7%, partial
response in 47%, stable disease in 31% and disease progression in
14% of the 42 patients. There was a strong correlation between SS-R
expression and response to therapy. Chromogranin-A levels showed
a clear decrease in patients with a complete or partial response.
CONCLUSION: This study showed promising results for radio-
nuclide therapy with 177Lu-DOTA0-Tyr3 Octreotate in patients
with neuroendocrine pancreatic tumors. Further studies are needed
to elucidate the somatostatin receptors and further tailor the receptor
radionuclide therapy.
51 HANDLING OF PANCREATICODUODENECTOMY
SPECIMENS INFLUENCES REPORTING OF
PROGNOSTICALLY RELEVANT FINDINGS
Verbeke CS1, Menon KV3, Guthrie A2, Toogood G3, McMahon
M3, Leitch D1, Prasad R3, (1) Department of Histopathology; (2)
Department of Radiology; (3) Department of Surgery, Leeds
Teaching Hospitals NHS Trust, Leeds, UK
INTRODUCTION AND AIM: Histopathological examination of
pancreaticoduodenectomy specimens (PDEs) resected for adeno-
carcinoma is difficult given their complex anatomy and extensive
circumferential resection margin (CRM). While the tumour origin
(pancreas, common bile duct (CBD) or ampulla), and the RM status
have prognostic significance, there is no standardized protocol (SP)
for the examination of these specimens. PATIENTS AND
METHODS: Histopathology data of a series reported according to
an SP for dissection, photodocumentation, CRM staining and tissue
sampling (SP, n=54) were compared to those of a stage-matched
series in which an SP had not been used (non-SP, n=48).
RESULTS: The proportion of pancreatic, ampullary and CBD
cancers diagnosed in both series differed significantly (SP: 48%,
28%, 24% vs non-SP: 75%, 17%, 8%). In the SP series the R1 rate
(tumour 51 mm to RM) was high (59% vs 46% in non-SP) and
showed significant differences between pancreatic (85%), ampullary
(27%) and CBD (42%) cancer. Extensive sampling of the CRM in
the SP series (8 vs 4 blocks/case in non-SP series) revealed frequent
involvement of the retroperitoneal and lateral CRM and rare posi-
tivity of the transection margin (46%, 30%, 4%). Lymph node yield
(16 vs 11/case) and rate of vascular invasion (69% vs 35%) were
higher in the SP series. There was no significant difference in the
survival of patients in the non-SP series (R0 vs R1) while in the SP
series there was a significant difference (R0 vs R1) (log rank test,
p=0.001). CONCLUSION: The handling of PDEs influences the
detection of prognostically important findings and standardization is
needed to allow consistent reporting, as this does have implications in
terms of survival.
52 USEFULNESS OF 18-FDG PET IN THE FOLLOW-UP
AFTER RESECTION OF PANCREATIC AND
PERIAMPULLARY CARCINOMAS
Sperti C1, Pedrazzoli S4, Pasquali C1, Bissoli S2, Fiore V2, Scelzi E3,
Mion M3 , (1) Scienze Mediche e Chirurgiche, Universita` di Padova,
Padova, Italy; (2) Nuclear Medicine, Castelfranco Veneto Hospital
(Treviso), Italy; (3) Medical Oncology, Castelfranco Veneto
Hospital (Treviso), Italy; (4) Clinica Chirurgica IV, Scienze Mediche
e Chirurgiche, Padova, Italy
INTRODUCTION AND AIM: Detection of recurrence after
resection of pancreatic and periampullary malignancies is often
difficult, and recurrent disease, when detected, is usually incurable.
In this study we tried to determine the role of 18-FDG PET in
detecting recurrences. PATIENTS AND METHODS: From Janu-
ary 1998 to December 2003, 42 patients (18 males and 24 females,
mean age 62.7 years, range 37–84) underwent FDG PET after
resection of pancreatic (n=29) or periampullary cancers (n=13). All
patients underwent US, helical CT, chest X-ray and serum tumour
markers assay (CEA and CA 19-9). Mean follow-up was 29.3
months, range 6–76. RESULTS: 28 patients showed tumour
recurrence; 21 (75%) had high serum CA 19-9 levels. Sensitivity of
FDG PET and CT scan in detecting tumour relapse was 91% (27/
28) and 57% (16/28), respectively. Nine of 12 patients with FDG
PET-positive/CT scan-negative recurrent tumours were asympto-
matic: 5 patients underwent resection (3 paraortic lymph-nodes, 2
liver metastasis), 5 chemotherapy, 1 radiotherapy, and 1 supportive
therapy. A second primary tumour was detected by FDG PET and
resected in three patients (1 lung and 2 colon carcinomas). A wedge
hepatic resection was performed for a CT scan-positive, FDG PET-
negative lesion. 11 patients showed no recurrence: FDG PET was
negative in all patients, while one patient had transient elevation of
CA 19-9 levels and 3 had equivocal CT or US findings. FDG PET
altered the clinical management in 8/31 (26%) patients.
CONCLUSION: FDG PET is very sensitive in detecting recurrent
periampullary carcinomas, allowing changes in the management in
one quarter of the patients.
53 RISK-ADJUSTED PREDICTION OF OPERATIVE
MORBIDITY IN PATIENTS UNDERGOING
PANCREATODUODENECTOMYWITHTHEUSEOF POSSUM
de Castro SMM, Houwert JT, Kuhlmann KFD, Busch ORC, van
Gulik TM1, Obertop H, Gouma DJ, Surgery, Academic Medical
Center, Amsterdam, The Netherlands
INTRODUCTION AND AIM: Comparison of operative morbidity
rates after pancreatoduodenectomy between units may be misleading
because it does not account for the physiological variation of the
condition of the patient. The aim of the study was to evaluate the ap-
plicability of the Physiological and Operative Severity Score for the
enUration of Mortality and Morbidity (POSSUM) for patients who
undergo pancreatoduodenectomy and to look for specific risk factors
associated with morbidity in a high volume center. PATIENTS AND
METHODS: Between January 1993 and December 2003, 511
patients underwent a pancreatoduodenectomy of which 424 (83%)
were for malignant disease. POSSUM was calculated according to
the generally accepted criteria. The performance of POSSUM was
evaluated by assessing the ‘goodness-of-fit’ using the exponential
analysis method using observed to predicted morbidity (O : P) ratio.
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Secondly, predictive factors of interest associated with morbidity
were analyzed using univariate and multivariate analysis. RESULTS:
Overall, 285 of 511 patients (51%) had one or more complication
after pancreatoduodenectomy and 7 patients (1.4%) died. The O:P
ratio for POSSUM was 1.09. In multivariate analysis, four statisti-
cally significant factors associated with an increased morbidity
(p50.05) were identified: hypertension (OR=1.86, 95% CI:
1.10–3.14), advanced age476 years (4th quartile) (OR=1.73, 95%
CI: 1.01–2.95), male gender (OR=1.56, 95% CI: 1.05–2.94) and
ampulla of Vater adenocarcinoma (OR=1.66, 95% CI: 1.01–2.75).
CONCLUSION: Overall, POSSUM performed well and may serve
as a useful comparative audit tool for patients who undergo
pancreatoduodenectomy. A dedicated PAN-POSSUM model can be
made by adjusting for tumor pathology as this was the only factor
which was not incorporated in POSSUM.
54 PANCREATIC RESECTIONS AFTER PRIMARY
CHEMO-RADIOTHERAPY FOR LOCALLY ADVANCED
ADENOCARCINOMA
Massucco P, Lotesoriere R, Ribero D, Vigano` L, Capussotti L,
Surgical Oncology, IRCC Candiolo, Candiolo, Torino, Italy
INTRODUCTION AND AIM: We analysed pancreatic resections
performed in the setting of a phase II study designed to evaluate
primary chemoradiation in patients with locally advanced pancreatic
cancer. PATIENTS AND METHODS: From 1/1999 to 6/2003, 25
patients received GEM (100 mg/m2 twice-weekly for the first 15
cases and 50 mg/m2 in the remaining) concurrently with RT (45 Gy;
1.8 Gy/d). All patients had biopsy-proven disease and were restaged
by CT scan 45 days after the end of treatment. Patients showing PR
or SD with normalisation of CA19.9 were surgically explored.
RESULTS: Eight patients (5 PR and 3 SD with normalisation of
CA19.9) were explored. Surgery: 4 duodenopancreatectomies and 4
total pancreatectomies; 2 vein resections. Mean operative time was
1 h longer than pancreatic resections consecutively performed in the
same period for 40 localized ductal carcinomas (6.6 h+0.5 vs 5.6 h
+0.9; p50.02). One patient died 2 months after surgery following a
biliary leak. Morbidity: 1 pancreatic fistula and 1 delayed gastric
emptying. Pathologic findings: microscopic cancer foci in 2 cases;
pT3N0 in 4; pT3N1 in 2. Median and 24-months survival were 21%
and 31% for resected cases vs 11% and 0% for non-resected,
respectively. In the group of 40 patients with localised cancer these
figures were 18% and 35%. CONCLUSION: Pancreatic resection
after combined treatment is feasible but more technically demand-
ing. Both CT scan and serum CA19-9 were useful in the selection of
patients to be surgically explored. Patient undergoing a pancreatic
resection experienced a longer survival than non-resected and
comparable to patients resected for localized cancer.
55 THE VALUE OF FROZEN SECTION PANCREATIC
BIOPSIES
Doucas H1, Neal C1, O’Reilly K2, Dennison A1, Berry D1,
(1) Department of Hepatobiliary and Pancreatic Surgery; (2)
Department of Pathology, Leicester General Hospital, Leicester, UK
INTRODUCTION AND AIM: Patients with potentially resectable
pancreatic masses, without evidence of metastatic disease, require
surgical exploration. We assessed the reliability of frozen section
diagnosis of pancreatic malignancy. PATIENTS AND METHODS:
We analysed data from 120 patients, with a mean age of 61.6 years,
who underwent pancreatic exploration, including frozen section
assessment, over a period of 41 months. RESULTS: A total of 310
pancreatic biopsies were sent for frozen section analysis. There was
98.1% concurrence with histology on formalin-fixed tissue. The false
negative rate was 1.9%, with the correct diagnosis being established
on subsequent frozen section in half of these cases. The majority of
tumours identified were adenocarcinomas, but endocrine tumours,
lymphoma, and carcinoid were also detected. 15 (12.5%) patients
required more than one set of biopsies in order to establish a diag-
nosis of malignancy. 19 (15.8%) patients had malignant disease
outside the pancreas diagnosed on frozen section biopsy, making
their tumours unsuitable for curative resection. CONCLUSION:
Frozen section biopsy is 98.1% accurate in establishing the correct
diagnosis of pancreatic masses. More than one biopsy is needed to
make a diagnosis, and if clinically suspicious, successive sets of
biopsies may be required.
56 SIGNIFICANCE OF ISOLATED TUMOR CELLS IN
LYMPH NODES AMONG PANCREATIC CANCER PATIENTS
Milsmann C3, Fu¨zesi L1, Werner C2, Becker H3, Horstmann O3, (1)
Department of Pathology; (2) Department of Medical Statistics; (3)
Department of General Surgery, University Clinic Go¨ttingen,
Go¨ttingen, Germany
INTRODUCTION AND AIM: To determine the frequency and
prognostic impact of isolated tumor cells (ITC) in regional lymph
nodes judged to be tumor-free in conventional histopathology among
pancreatic cancer patients. PATIENTS AND METHODS: Among
115 patients who underwent pancreatic resection for malignoma, 48
were staged pN0 (42%). Archival paraffin blocks of 271 resected
regional lymph nodes of 41 pN0 patients were re-evaluated for ITC
using monoclonal antibody Ber-EP4 (7 patients without archival
lymph nodes). Patients with and without ITC were compared with
regard to the distribution of various clinicopathological factors.
Prognostic impact of ITC was tested in univariate and multivariate
analysis. RESULTS: Of 41 pN0 patients, 16 (39%) exhibited single
Ber-Ep4 immunoreactive cells or small cell clusters in at least one
lymph node (pN0(i+)). The occurrence of ITC was not dependent
on other clinicopathological factors, except for the tumor type: in
distal bile duct carcinoma, ITC were encountered in each case
(100%), whereas they were less frequent in carcinoma of the ampulla
(20%) and pancreatic adenocarinoma (36%, p=0.009). ITC
impaired patients’ prognoses significantly in univariate as well as
multivariate analyses (estimated 5-year survival rate: 53% for pN0(i-)
vs 10% for pN0(i+) and 9% for pN1/2, p=0.0047). CONCLU-
SION: ITC are a frequent event in apparently tumor-free lymph
nodes of pancreatic cancer patients and overlooked by conventional
histopathology. They are encountered even in limited stages of
disease and impair patients’ prognoses, which is then comparable to
true lymph node metastasis. It remains to be further resolved whether
those patients may benefit from adjuvant therapy.
57 RELEVANCE OF COLOR DOPPLER
ECHOSONOGRAPHY FINDINGS IN ASSESSMENT OF
PANCREATIC CARCINOMA RESECTABILITY
Alempijevic T1, Kovacevic N1, Milicevic M2, Krstic M1, (1) Clinic
for Gastroenterohepatology; (2) Clinic for Abdominal Surgery,
Clinical Center of Serbia, Belgrade, Serbia & Montenegro
INTRODUCTION AND AIM: It is highly desirable to achieve the
most accurate diagnostic information possible with more noninvasive
technology. By defining tumor involvement of blood vassals color
Doppler sonography has been increasingly reported as an effective
screening tool for clinical staging and treatment decisions in patients
with pancreatic neoplasms. Our study aims to analyze sensitivity and
specificity of data gathered by different diagnostic techniques in
patients with pancreatic neoplasm that are important for treatment
decisions. PATIENTS AND METHODS: In presurgical assess-
ment of patients with pancreatic neoplasm, we applied color Doppler
ultrasonography, angiography, and endosonography. Patients with
metastasis of pancreatic neoplasm were excluded from this study. We
examined 27 patients who underwent surgery. Findings of color
Doppler ultrasonography were compared with the findings obtained
by other techniques, as well as with operative findings. RESULTS:
There were 18 male and 9 female patients, aged 41–80 years (mean
age 58.5). Of the 27 patients, 11 patients underwent a radical surgical
procedure, while the rest had palliative operation. Tumor invasion of
blood vessels was critical in the decision-making process for the type
of surgical treatment. Comparison of color Doppler sonograms and
operative findings show that sensitivity of color Doppler sonography
for detection of vascular involvement was 80.8% (42/52), whereas its
specificity was 83% (112/135), sensitivity of angiography was 70.4%
(38/54), and its specificity was 100% (142/142), while sensitivity of
endosonography was 90.7% (49/54), and its specificity 85.9% (122/
142). CONCLUSION: In comparison to other methods for
prediction of pancreatic, neoplasm resectability color Doppler
sonography shows a satisfactory rate of sensitivity and specificity. As
color Doppler sonography is a noninvasive and inexpensive techni-
que, and considering results of our study and other similar studies, it
appears that color Doppler sonography should be used as the initial
method for detection of vascular invasion in preoperative assessment
of patients with pancreatic neoplasm.
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58 MESENTERIC-PORTAL VEIN RESECTION DURING
PANCREATECTOMY FOR DUCTAL ADENOCARCINOMA OF
THE PANCREAS
Boggi U1, Del Chiaro M1, Croce C1, Gremmo F1, Sgambelluri AF1,
Balzano E1, Funel N2, Cappelli C3, Campani D2, Mazzeo S3,
Mosca F1, (1) Division of General and Transplant Surgery;
(2) Pathology; (3) Radiology, University of Pisa, Pisa, Italy
INTRODUCTION AND AIM: Mesenteric-portal vein (MPV)
involvement has been traditionally considered a contraindication for
resection of ductal adenocarcinoma of the pancreas (DAP).
However, vein involvement often cannot be ruled out until transec-
tion of pancreatic neck and actual prognostic implication of surgically
infiltrated MPV has not been defined completely yet. The aim was to
analyse the prognostic implications of MPV infiltration in DAP and
the postoperative and long-term results of pancreatectomies asso-
ciated with MPV resections. PATIENTS AND METHODS: From
November 1987 to May 2004, 128 pancreatectomies associated with
vascular resection were performed at our institution. Overall there
were 94 vein resections (73.4%) including 77 done for DAP. The
mean age of the patients was 64.9 years (range 37–84). 39 patients
were male (50.6%) and 35 female (49.4%). 48 patients (62.3%)
underwent pancreaticoduodenectomy, 23 (29.9%) total pancrea-
tectomy and 6 (7.8%) subtotal distal pancretectomy. RESULTS:
Vascular infiltration was histologically confirmed in 42 cases
(54.5%). Postoperative morbidity and mortality rates were 37.6%
(29/77) and 2.5% (2/77), respectively. 1-, 3- and 5-year survival
rates for the patients who underwent pancreatectomies associated
with MPV resection were 55%, 18.7% and 10.2%, respectively. 1-,
3- and 5-year survival rates of patients with histologically un-
confirmed vascular infiltration were significantly higher as
compared with patients with confirmed vascular infiltration (72.1%,
30.1% and 20.1% vs 47.7%, 5.6% and 5.6%; p=0.025).
CONCLUSION: MPV resection neither increases the risk of
pancretectomies, nor reduces long-term survival as compared to
standard pancreatectomies. Interestingly, lack of histologic proof
of tumor involvement is associated with statistically relevant survival
benefit.
59 COMBINED ENDOSCOPIC AND LAPAROSCOPIC
ULTRASOUND IN THE EVALUATION OF RESECTABILITY
IN PANCREATIC CANCER
Nielsen HO, Fristrup C, Mortensen M, Pless T, Durup J,
Ainsworth A, Hovendal C, Department of Surgical
Gastroenterology, Odense University Hospital, Odense, Denmark
INTRODUCTION AND AIM: An accurate pretherapeutic assess-
ment of the resectability in pancreatic cancer patients is essential in
order to reduce the number of futile surgical explorations. The aim of
this study was to assess the combination of endoscopic ultrasound
(EUS) and laparoscopic ultrasound (LUS) in the detection of patients
with non-resectable tumors. PATIENTS AND METHODS: From
2002 to 2004, 166 consecutive patients with pancreatic cancer
referred for surgical treatment were included. 28 (17%) patients were
excluded due to co-morbidity and poor perfomance status. Patients
were first examined with EUS followed by LUS, if EUS found no
signs of non-resectability. Only patients found to be resectable or
possibly resectable at EUS and LUS were offered surgical treatment.
Resectabilty criteria were defined prior to the study. RESULTS: 102
(74%) patients were non-resectable by the defined criteria. EUS
identified 65 (64%) patients (43 due to tumor size, 7 due to meta-
stasis and 15 due to both) and LUS identified an additional 24 (24%)
patients (13 due to tumor size, 10 due to metastasis, 1 with aortic
aneurysm). Thus, a total of 89 (87%) patients were non-resectable at
either EUS or LUS. 49 (36%) patients underwent surgery. Five
patients had surgical exploration and three patients had palliative
surgery. 41 patients were resected with curative intention of which 36
had an R0 resection and 5 had a palliative resection. CONCLU-
SION: The combination of EUS and LUS is highly efficient in
identifying non-resectable patients and this strategy can reduce the
need for surgical exploration.
60 RADIOFREQUENCY ABLATION (RFA) IN
PANCREATIC CANCER
Hadjicostas P1, Symeonidis P1, Malakounidis N1, Varianos C1,
Kitiris E1, Lerni F2, (1) Surgical Department; (2) Anesthesiology
Department, Nicosia’s General Hospital, Strovolos, Nicosia, Cyprus
INTRODUCTION AND AIM: RFA is effective in the treatment of
unresectable hepatic tumors and promising results also have been
described in tumors of kidney, lung, brain, prostate and breast. The
radiofrequency (RF) destruction of solid pancreatic tumors sounds
logical but also seems risky due to the friable pancreatic parenchyma,
the fear of pancreatitis and the prejudiced myth that the pancreas is
not your friend. PATIENTS AND METHODS: We present our
initial experience and we describe our technique during intraopera-
tive RFA in 3 patients with locally advanced and unresectable
pancreatic adenocarcinoma (head of pancreas 2, body-tail 1/median
d: 7 cm). In all, the RFA was followed by bypass palliative procedures
(cholecysto-jejunostomy and Brown’s anastomosis and/or gastro-
jejunostomy). Drainage tube was left close to the ablated area. Serum
amylase and fluid amylase (drain) was measured for 5–7 days post-
operatively. Sandostatin was also administered prophylactically for 5
days. RESULTS: In all the patients the postoperative period was
uneventful without complications or evidence of pancreatitis. The
post RFA CT scan showed in all remarkable changes in the density
and the characteristics of the tumors (?destruction). The patients are
alive (8 months, 2 months, 3 weeks postoperatively). In one patient
(Ca of the body of pancreas) who was on morphine because of
intolerable pain a significant pain relief has been observed.
CONCLUSION: From our initial results, RFA seems to be a feasi-
ble, potentially safe and promising option in patients with locally
advanced and unresectable pancreatic cancer. Nevertheless, larger
series of cases are needed to secure our encouraging results.
61 DELAYED VISCERAL ARTERIAL BLEEDING AFTER
PANCREATIC HEAD RESECTION
Makowiec F, Hopt U, Adam U, Department of Surgery, University
of Freiburg, Freiburg, Germany
INTRODUCTION AND AIM: Despite low mortality complica-
tions are frequent after pancreatic head resection. The occurrence of
delayed visceral arterial bleeding (DVAB) from branches of the celiac
trunc or the gastroduodenal artery is rare but life-threatening and
under-reported in the literature. PATIENTS AND METHODS:
Since 1994, 464 pancreatic head resections were performed. DVAB
was defined as bleeding from branches of the celiac axis. We treated
12 patients with DVAB. Three of those were referred for bleeding.
RESULTS: The frequency of DVAB was 1.9%. DVAB occurred a
median of 24 days after surgery. Presentation was gastrointestinal
(n=7) or abdominal bleeding (n=5). Median transfusions were 12.5
units. Bleeding sites were the common hepatic (n=5), gastro-
duodenal (n=5), splenic (n=1) or pancreatoduodenal artery (n=1).
Angiography was performed in 10 patients and controlled bleeding in
6. One patient died during angiography. In three patients bleeding
control was not possible, they underwent surgery. Surgical control
was obtained in 5 patients by ligatures of the common hepatic artery
(2), gastroduodenal artery (2) and splenic artery (1). Of the surviving
11 patients all 6 with maintained hepatic artery blood flow had an
uneventful further course. After hepatic artery occlusion 4/5 patients
had complications (3 liver abcess, one bile leak). One of the patients
with liver abscesses died 4 months later. CONCLUSION: DVAB
bleeding is a severe complication after pancreatic head resection. In
the most frequently encountered lesions of the common hepatic
artery or the gastroduodenal artery stump bleeding control should
optimally be achieved by angiographic stenting, as the preservation of
hepatic blood flow prevents further severe complications.
62 PERIAMPULLARY TUMORS: EXPERIENCE
WITH 945 CASES
Fathy OM2, El-Ebidy G1, Kandiel T1, El-Shobari M1, (1) ERCP,
Gastroenterology Surgical Center; (2) Surgery, Gastroenterology
Surgical Center, Mansoura, Egypt
INTRODUCTION AND AIM: The aim of this work is to evaluate
the outcome of different modalities of treatment of patients with
periampullary tumors, surgical resection (Whipple operation), versus
palliative bypass (surgical or endoscopic). PATIENTS AND
METHODS: In the period from 1995 to 2001, 945 patients were
included in this study. Mean age was 58+11 years with no statistical
significant difference between different groups. Male to female ratio
was 1.64 : 1. Larger mass mean size was detected in irresectable
tumors: 51+18 mm compared to 37+16 mm in patients who
underwent surgical resection. RESULTS: Surgical resection could
be achieved in 216 cases (22.9%), in 182 (84.7%) the recon-
struction was by pancreaticogastrostomy and in 33 (15.3%) by
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pancreaticojejunostomy. A comparative study between the 2
modalities of reconstruction proved the superiority of pancreatico-
gastrostomy. Surgical palliative bypass was done in 100 cases
(10.6%), in 88 cases by choledochojejunostomy Roux-en-Y, in the
other 12 cases cholecystojejunostomy was performed. The latter
procedure is not recommended any more. In the remaining 629
advanced cases endoscopic stenting was done as permanent
drainage. The net results show that although endoscopic stent had
the shortest hospital stay (2.5+5.8 days), it needs several read-
missions ranging from 1 to 5 times, while hospital stay after surgical
resection and surgical bypass was 11.7+8.6 and 5.9+3, respectively.
CONCLUSION: Surgery gives the best long-term result, endoscopic
stenting is reserved for palliation in poor risk patients.
63 PERIPHERAL INTRADUCTAL PAPILLARYMUCINOUS
NEOPLASMS: WHERE ARE WE GOING?
Salvia R1, Bassi C1, Falconi M1, Guarise A2, Serini P1, Crippa S1,
Marcucci S1, Pederzoli P1, (1) Surgery, University of Verona;
(2) Radiology, University of Verona, Verona, Italy
INTRODUCTION AND AIM: Some authors showed that ‘branch-
duct’ intraductal papillary mucinous neoplasms (IPMNs) may have a
less aggressive biological behaviour, suggesting limited resection or,
at least, a conservative surgical treatment. The aim was to analyse our
decision making in the branch-duct IPMNs. PATIENTS AND
METHODS: All patients with a diagnosis of peripheral IPMN
observed or treated by resection in the Surgical Department of the
University of Verona over the period from 1990 to June 2004 were
included in the study. All patients observed were submitted to
MRCP to confirm the communication with the main duct.
RESULTS: We considered 144 pts (53%) affected by peripheral
IPMN over 272 with a final diagnosis of IPMN. In this group we
resected 56 (39%) (Group A), the final diagnosis was adenoma in 22
(39.3%), 17 (30.4%) borderline, 9 (16%) in situ carcinoma and 8 pts
(14.3%) had invasive carcinoma. The pts observed with a
presumptive diagnosis of peripheral still benign IPMNs are 88 (61%)
(Group B). The median age in the two groups was 62.3 and 64.1
years, respectively, the rate of asymptomatic patients was 17.8% vs
100% (p50.01); the median diameter of the lesions was 40 mm in
Group A and 17 mm in Group B. Five patients were submitted to
resection during the follow-up (5.7%) and the final diagnosis was
adenoma in 2 and borderline in 3. CONCLUSION: This is the first
report in the literature about the follow-up of a large series of
peripheral IPMNs. We agree with the tendency of less aggressiveness
of the peripheral IPMNs. The final diagnosis of the resected
peripheral IPMNs demonstrates that the clinical-laboratory-
radiological parameters that we usually use are helpful to distinguish
benign from malignant IPMNs previous surgery.
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